Publikationen
Suche in Publikationen
2013
Bid-ding for mercy: twisted killer in action.
Egle A, Asslaber D, Villunger A, Pinon-Hofbauer J.
Cell Death and Differentiation. 2013 Jul;20(7):847-9. doi: 10.1038/cdd.2013.40.
15.06.2013
Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer.
Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezínková H, Awada A.
Journal of Clinical Oncology.
03.06.2013
p53 Efficiently Suppresses Tumor Development in the Complete Absence of Its Cell-Cycle Inhibitory and Proapoptotic Effectors p21, Puma, and Noxa.
Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL, Janic A, Strasser A.
Cell Reports. 2013 May 7. doi:pii: S2211-1247(13)00179-4. 10.1016/j.celrep.2013.04.012. [Epub ahead of print]
07.05.2013
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, von Lilienfeld-Toal M, Brugger W, Derigs HG, Kremers S, Greil R, Raghavachar A, Ringhoffer M, Salih HR, Wattad M, Kirchen HG, Runde V, Heil G, Petzer AL, Girschikofsky M, Heuser M, Kayser S, Goehring G, Teleanu MV, Schlegelberger B, Ganser A, Krauter J, Bullinger L, Döhner H, Döhner K.
Blood. 2013 Apr 30. [Epub ahead of print]
30.04.2013
Azacitidine in patients with WHO-defined AML -- results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.
Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, Steinkirchner S, Melchardt T, Mitrovic M, Girschikofsky M, Lang A, Krippl P, Sliwa T, Egle A, Linkesch W, Voskova D, Angermann H, Greil R.
Journal of Hematology & Oncology. 2013 Apr 29;6(1):32. [Epub ahead of print]
29.04.2013
AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab as First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer.
Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V.
Journal of Clinical Oncology. 2013 Apr 8. [Epub ahead of print]
08.04.2013
Invasive Candida Infektionen. Diagnostik und Therapie.
Apfalter P, Auberger J, Bellmann R, Forstner C, Gattringer R, Girschikofsky M, Janata O, Keil F, Krause R, Weiss G, Wenisch C, Willinger B.
Österreichische Ärztezeitung. Supplementum April 2013
04/2013
Using cyclophosphamide in inflammatory rheumatic diseases.
Brummaier T, Pohanka E, Studnicka-Benke A, Pieringer H.
European Journal of Internal Medicine. 2013 Mar 22. doi:pii: S0953-6205(13)00051-4. 10.1016/j.ejim.2013.02.008. [Epub ahead of print]
22.03.2013
Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.
Pfeiler G, Stöger H, Dubsky P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U, Renner K, Ploner F, Steger GG, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, Greil R, Fesl C, Gnant M.
British Journal of Cancer. 2013 Mar 19. doi: 10.1038/bjc.2013.114. [Epub ahead of print]
19.03.2013
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.
Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, Cramer P, Reinart N, Winkler D, Fingerle-Rowson G, Stilgenbauer S, Döhner H, Kandler G, Eichhorst B, Hallek M, Herling M.
Cancer. 2013 Mar 19. doi: 10.1002/cncr.27972. [Epub ahead of print]
19.03.2013
ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials.
Böll B, Görgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P.
Journal of Clinical Oncology. 2013 Mar 18. [Epub ahead of print]
18.03.2013
A modified Phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients.
Hufnagl C, Stöcher M, Moik M, Geisberger R, Greil R.
Journal of Nucleic Acids Investigation. 2013. DOI: 10.4081/jnai.2013.e1
11.03.2013
A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p.
Namberger K, Weiss L, Kofler B, Melchardt T, Greil R.
Eur J Haematol. 2013 Apr;90(4):349-50. doi: 10.1111/ejh.12065. Epub 2013 Feb 14
14.02.2013
Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo.
Lutzny G, Kocher T, Schmidt-Supprian M, Rudelius M, Klein-Hitpass L, Finch AJ, Dürig J, Wagner M, Haferlach C, Kohlmann A, Schnittger S, Seifert M, Wanninger S, Zaborsky N, Oostendorp R, Ruland J, Leitges M, Kuhnt T, Schäfer Y, Lampl B, Peschel C, Egle A, Ringshausen I.
Cancer Cell. 2013 Jan 14;23(1):77-92. doi: 10.1016/j.ccr.2012.12.003.
19.01.2013
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; on behalf of the Central European Cooperative Oncology Group.
Lancet Oncology. 2013 Jan 9. [Epub ahead of print]
09.01.2013
Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia.
Valentiny C, Mitrovic M, Pleyer L, Steurer M, Willenbacher W, Stauder R.
Wiener Klinische Wochenschrift. 2013 Jan;125(1-2):50-3. doi: 10.1007/s00508-012-0319-6. Epub 2013 Jan 5.
05.01.2013
Viral infections and their management in patients with chronic lymphocytic leukemia.
Melchardt T, Weiss L, Greil R, Egle A.
Leuk Lymphoma. 2013 Jan 3.
03.01.2013
2012
Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient.
Taylor N, Melchardt T, Grundbichler M, Strasser M, Egle A, Greil R.
Annals of Hematology. 2012 Dec 28.
28.12.2012
Utility of PCR in the Diagnosis of Invasive Fungal Infections: Real Life Data from a Multi-Centre Study.
Lass-Floerl C, Mutschlechner W, Aigner M, Grif K, Marth C, Girschikofsky M, Grander W, Greil R, Russ G, Cerkl P, Eller M, Kropshofer G, Eschertzhuber S, Kathrein H, Schmid S, Beer R, Lorenz I, Theurl I, Nachbaur D.
Journal of Clinical Microbiology. 2012 Dec 26.
26.12.2012
Topical evening primrose oil for reduction of bortezomib-induced skin reactions.
Auberger J, Vogt S, Hopfinger G, Clausen J, Greil R.
Annals of Hematology. 2012 Dec 22.
22.12.2012
CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8.
Goetz MP, Suman V, Hoskin TL, Gnant M, Filipits M, Safgren S, Kuffel MJ, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilboum RM, Ames M, Ingle JN.
Clinical Cancer Research. 2012 Dec 4. [Epub ahead of print]
04.12.2012
Mimicking the microenvironment in chronic lymphocytic leukaemia - where does the journey go?
Asslaber D, Grössinger EM, Girbl T, Hofbauer SW, Egle A, Weiss L, Greil R, Hartmann TN.
British Journal of Haematology. 2012 Dec 4. doi: 10.1111/bjh.12151. [Epub ahead of print]
04.12.2012
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; on behalf of the ML18147 Study Investigators.
Lancet Oncology. 2012 Nov 15.
15.11.2012
GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer.
Rick FG, Seitz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Buchholz S, Block NL, Hohla F.
Cell Cycle. 2012 Volume 11 Issue 22. [Epub ahead of print]
15.11.2012
Upgraded Cobas TaqMan version 2: hidden consequences at cohort level.
Taylor N, Grabmeier-Pfistershammer K, Oberkofler H, Egle A, Rieger A, Ledergerber B.
Journal of the International AIDS Society. 2012 Nov 11;15(6):18207. doi: 10.7448/IAS.15.6.18207.
11.11.2012
A 55-year-old woman with locally advanced rectal cancer and a resectable synchronous hepatic metastasis: a case report.
Hohla F, Mayer P, Hutter J, Meißnitzer T, Greil R.
Memo - Magazine of European Medical Oncology. Case Report
05.11.2012
CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21 induced motility.
Girbl T, Hinterseer E, Grössinger EM, Asslaber D, Oberascher K, Weiss L, Hauser-Kronberger C, Neureiter D, Kerschbaum H, Naor D, Alon R, Greil R, Hartmann TN.
Cancer Research. 2012 Nov 1. [Epub ahead of print]
01.11.2012
What paths are open for tackling increasing azole resistance in Aspergillus in the clinic?
Auberger J, Greil R, Lass-Flörl C.
Expert Review of Anti-Infective Therapy. 2012 Nov;10(11):1229-31.
11/2012
What is causing my arthritis, doctor? A glimpse beyond the usual suspects in the pathogenesis of rheumatoid arthritis.
Pieringer H, Studnicka-Benke A.
QJM. 2012 Oct 24. [Epub ahead of print]
24.10.2012
Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma.
Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Ricci D, Cakana A, Enny C, Feng H, van de Velde H, Harousseau JL.
Journal of Clinical Oncology.
22.10.2012
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.
Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, Kenner L.
Nature Medicine. 2012 Oct 14. doi: 10.1038/nm.2966. [Epub ahead of print]
14.10.2012
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M; on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Annals of Oncology. 2012 Oct 3. [Epub ahead of print]
03.10.2012
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.
Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, Fernebro E, Gamelin E, Banos A, Köhne CH.
BMC Cancer. 2012 Sep 29;12(1):438. [Epub ahead of print]
29.09.2012
Novel treatment avenues for peripheral T-cell lymphomas.
Hopfinger G, Griessl R, Sifft E, Taylor N, Kenner L, Greil R, Merkel O.
Expert Opinion on Drug Discovery. 2012 Sep 24. [Epub ahead of print]
24.09.2012
Treating T-cell lymphoma: is there a light at the end of the tunnel?
Hopfinger G, Merkel O, Melchardt T, Greil R.
Memo - Magazine of European Medical Oncology. (2012) 5:174–177
DOI 10.1007/s12254-012-0013-4
18.09.2012
Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue-Lymphoma: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie.
Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, Greil R, Raderer M.
Haematologica-The Hematology Journal. 2012 Sep 14. [Epub ahead of print]
14.09.2012
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Keil F, Selzer E, Berghold A, Reinisch S, Kapp KS, De Vries A, Greil R, Bachtiary B, Tinchon C, Anderhuber W, Burian M, Kasparek AK, Elsäßer W, Kainz H, Riedl R, Kopp M, Kornek G.
European Journal of Cancer. 2012 Sep 13. pii: S0959-8049(12)00629-6. doi: 10.1016/j.ejca.2012.08.004. [Epub ahead of print]
13.09.2012
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.
Reinacher-Schick A, Schulmann K, Modest D, Bruns N, Graeven U, Jaworska M, Greil R, Porschen R, Arnold D, Schmiegel W, Tannapfel A.
BMC Cancer. 2012 Aug 9;12(1):349.
09.08.2012
Histiocytic sarcoma - targeted therapy: novel therapeutic options? A series of 4 cases.
Schlick K, Aigelsreiter A, Pichler M, Reitter S, Neumeister P, Hoefler G, Beham-Schmid C, Linkesch W.
Onkologie. 2012;35(7-8):447-50. doi: 10.1159/000340066. Epub 2012 Jul 12.
12.07.2012
Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
Rick FG, Buchholz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Aigner E, Perez R, Seitz S, Block NL and Hohla F.
Cell Cycle. Volume 11, Issue 13 July 1, 2012
01.07.2012
Safety of immunosuppressants. [Article in German]
Psenak O, Studnicka-Benke A, Greil R.
Zeitschrift fur Rheumatologie. 2012 Jul;71(5):420-9.
07/2012
Influence of the American ODAC Statement on Austrian Bevacizumab Prescribing Practice for Metastatic Breast Cancer.
Preusser M, Fülöp G, Berghoff AS, Heinzl H, Steger GG, Greil R, Zielinski CC, Bartsch R.
Oncologist. 2012 Jun 27. [Epub ahead of print]
27.06.2012
Non-invasive transient elastography for the prediction of liver toxicity following hematopoietic SCT.
Auberger J, Graziadei I, Clausen J, Vogel W, Nachbaur D.
Bone Marrow Transplantation. 2012 Jun 18. doi: 10.1038/bmt.2012.113.
18.06.2012
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions.
Valent P, Gastl G, Geissler K, Greil R, Hantschel O, Lang A, Linkesch W, Lion T, Petzer AL, Pittermann E, Pleyer L, Thaler J, Wolf D.
Critical Reviews in Oncology/Hematology. 2012 Jun;82(3):370-7. Epub 2011 Sep 7.
14.06.2012
Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.
Jöhrer K, Obkircher M, Neureiter D, Parteli J, Zelle-Rieser C, Maizner E, Kern J, Hermann M, Hamacher F, Merkel O, Wacht N, Zidorn C, Scheideler M, Greil R.
Journal of Molecular Medicine-JMM. 2012 Jun;90(6):681-93. Epub 2011 Dec 29.
12.06.2012
Actinomycin D induces p53-independent cell death and prolongs survival in high risk chronic lymphocytic leukemia.
Merkel O, Wacht N, Sifft E, Melchardt T, Hamacher F, Kocher T, Denk U, Pinon Hofbauer J, Egle A, Scheideler M, Schlederer M, Steurer M, Kenner L and Greil R.
Leukemia. 2012 Jun 1. doi: 10.1038/leu.2012.147. [Epub ahead of print]
01.06.2012
Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, and Lymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, Jakesz R, Fitzal F, Filipcic L, Fridrik M, Greil R, Gnant M.
ANNALS OF SURGICAL ONCOLOGY. 2012 Jun;19(6):1808-17. Epub 2011 Dec 30.
01.06.2012
Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact.
Sterlacci W, Savic S, Schmid T, Oberaigner W, Auberger J, Fiegl M, Tzankov A.
American Journal of Clinical Pathology. 2012 Jun;137(6):946-56.
01.06.2012
Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study.
Auberger J, Lass-Flörl C, Aigner M, Clausen J, Gastl G, Nachbaur D.
Journal of Antimicrobial Chemotherapy. 2012 May 30.
30.05.2012
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Lang I, Inbar MJ, Kahán Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Messinger D, Brodowicz T, Zielinski C.
Eur J Cancer. 2012 Nov;48(17):3140-9. doi: 10.1016/j.ejca.2012.04.022. Epub 2012 May 26.
26.05.2012
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA, Augustson B, Horvath N, Joshua D, Mollee P, Prince M, Spencer A, Taylor K, Gastl AG, Greil R, Ludwig H, Iskrov I, Uss A, Fillet G, Schots R, van Droogenbroeck J, Maisnar V, Scudla V, Gregersen H, Attal M, Fermand JP, Jaccard A, Macro M, Rossi J-, Dölken G, Engelhardt M, Goldschmidt H, Knop S, Niederwieser D, Crotty G, Nagler A, Rowe J, Shpilberg O, Cafro AM, Caravita T, Foa R, Gobbi M, Zweegman S, Dmoszynska A, Hellmann A, Skotnicki AB, Abdulkadyrov K, Domnikova N, Osmanov E, Rossiev V, Rukavistin O, Alegre A, Capote FJ, Martino ML, Miguel JS, Ahlgren T, Bauer S, Stenner F, Cagirgan S, Schey S, Yong K, Kaplan P, Kyeting E, Lysa T, Maslyak Z, Pylypenko G, Tretyak N.
New England Journal of Medicine. 2012 May 10;366(19):1759-69.
10.05.2012
Dendritic Cells Activated by IFN-γ/STAT1 Express IL-31 Receptor and Release Proinflammatory Mediators upon IL-31 Treatment.
Horejs-Hoeck J, Schwarz H, Lamprecht S, Maier E, Hainzl S, Schmittner M, Posselt G, Stoecklinger A, Hawranek T, Duschl A.
Journal of Immunology. 2012 Apr 25. [Epub ahead of print]
25.04.2012
Jak 1/2 Inhibitoren in der Myelofibrose.
Egle A.
WMW- Skriptum Kongressjournal Band 9/ Heft 3
19.04.2012
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
Jäger U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, Mannhalter C,
Oberaigner W, Porpaczy E, Skrabs C, Einberger C, Drach J, Raderer M, Gaiger A,
Putman M, and Greil R.
Haematologica. 2012 Sep;97(9):1431-1438. Epub 2012 Apr 17
17.04.2012
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases - a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.
Schimanski CC, Mohler M, Schon M, van Cutsem E, Greil R, Bechstein WO, Hegewisch-Becker S, von Wichert G, Vohringer M, Heike M, Heinemann V, Peeters M, Kanzler S, Kasper S, Overkamp F, Samonigg H, Seehofer D, Kullmann F, Schmidtmann I, Smith-Machnow V, Gockel I, Lang H, Galle PR.
BMC Cancer. 2012 Apr 11;12(1):144.
11.04.2012
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial.
Dreger P, Döhner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W, Stadler M, Pfreundschuh M, Dührsen U, Brittinger G, Hensel M, Schetelig J, Winkler D, Bühler A, Kneba M, Schmitz N, Hallek M, Stilgenbauer S; German CLL Study Group.
Blood. 2012 May 24;119(21):4851-9. doi: 10.1182/blood-2011-09-378505. Epub 2012 Apr 5.
05.04.2012
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.
Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V; on behalf of the German Hodgkin Study Group, the Swiss Group for Clinical Cancer Research, and the Österreichische Arbeitsgemeinschaft für Klinische Pharmakologie und Therapie.
Lancet. 2012 Apr 3.
03.04.2012
Treatment of invasive aspergillosis in cancer patients.
Auberger J, Russ G, Greil R, Egle A.
Memo - Magazine of European Medical Oncology. Volume 4, Number 4, 266-272.
26.03.2012
The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).
Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F, Sevelda P, Watzke H, Winder G, Greil R, Lang A, Van Belle S, Schrijvers D, Verhoeven D, Demey W, Majois F, Bustin F, Andre C, Espie M, Hacini M, Hardy Bessard AC, Isambert N, Lortholary A, Souquet PJ, Hebbar M, Berretta M, Dazzi C, Ferrarini M, Locatelli M, Lorusso V, Marchetti P, Martoni A, Pastorelli D, Pignata S, Giordano M, Aerts J, Blaisse R, van der Wouw A, Peláez I, Antolin Novoa S, Salgado Pascual JE, Candel VA, Rodríguez-Lescure Á, Palomar L, Soriano Teruel V, Bayne M, McAdam K, Molassiotis A, Rankin E, Samuel L, Chatterjee A, Khan S, Davidson N, Flogegard M, Norberg B, Flygare P, Nordenskjold B.
Annals of Oncology. 2012 Aug;23(8):1986-92. Epub 2012 Mar 6.
06.03.2012
Primary Immune Thrombocytopenia in Adults - Diagnostics and Treatment Consensus Statement of the Austrian Society of Hematology and Oncology (ÖGHO).
Pabinger I, Gastl G, Steurer M, Sormann S, Fillitz M, Friedl J, Geissler D, Geissler K, Greil R, Knöbl P, Kozek-Langenecker S, Krippl P, Kyrle P, Lang A, Linkesch W, Ludwig H, Müller M, Panzer S, Pittermann E, Thaler J, Weltermann A.
Wiener Klinische Wochenschrift. 2012 Mar 3.
03.03.2012
Canonical and Noncanonical Hedgehog/GLI Signaling in Hematological Malignancies.
Aberger F, Kern D, Greil R, Hartmann TN.
Vitamins & Hormones. 2012;88:25-54.
01.03.2012
Lysine Residue at Position 22 of the AID Protein Regulates Its Class Switch Activity
Geisberger R, Huemer M, Gassner FJ, Zaborsky N, Egle A, Greil R.
PLoS ONE. 2012. 7(2): e30667.
20.02.2012
Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?
Jöhrer K, Hofbauer SW, Zelle-Rieser C, Greil R, Hartmann TN.
Expert Opinion on Biological Therapy. 2012 Feb 15.
15.02.2012
First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study.
Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, Chan A, Delaloge S, Huang X, Kern KA, Giorgetti C.
Journal of Clinical Oncology. 2012 Feb 13.
13.02.2012
Supportive Therapie bei Tumorpatienten.
Hohla F, Faber V, Greil R.
Med.ium. 2/3 2012, p. 28-33.
02/2012
Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial.
von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A.
Journal of Clinical Oncology. 2012 Jan 23. [Epub ahead of print]
23.01.2012
Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group.
Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M.
Journal of Clinical Oncology. 2012 Jan 23.
23.01.2012
Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.
Rick FG, Schally AV, Szalontaya L, Block NL, Szepeshazia K, Nadjib M, Zarandi M, Hohla F, Buchholz S, Seitz S.
Proceedings of the National Academy of Sciences of the United States of America. 2012 109 (5) 1655-1660; published ahead of print January 18, 2012.
18.01.2012
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.
Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M.
Journal of Cancer Research and Clinical Oncology. 2012 Jan;138(1):65-72. Epub 2011 Sep 30.
01.01.2012
Chronische Lymphatische Leukämie (CLL).
Wendtner C, Dreger P, Gregor M, Greil R, Knauf W, Schetelig J, Steurer M, Stilgenbauer S.
Onkopedia. Jan 2012. http://www.dgho-onkopedia.de/onkopedia/leitlinien/cll
2012
Panitumumab (Vectibix) eine gleichwertige Alternative zu Cetuximab (Erbitux) in der Erst, Zweit sowie Drittlinentherapie des metastasierten Kolorektalkarzinoms.
Hohla F, Greil R.
Med.ium. 1/2012, p.22-25.
2012
2011
Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.
Fätkenheuer G, Duvivier C, Rieger A, Durant J, Rey D, Schmidt W, Hill A, van Delft Y, Marks S; on behalf of the SENSE Study Team.
Journal of Antimicrobial Chemotherapy. 2011 Dec 29.
29.12.2011
Anaplastic large cell lymphoma: the current state of play from a European prospective as presented at the second annual meeting of the European Research Initiative on ALCL, 27-28 June 2011.
Merkel O, Kenner L, Turner SD.
Leukemia. Dec;25(12):1795-6. doi: 10.1038/leu.2011.295.
12/2011
Detection of human papillomavirus type 18 E7 oncoprotein in cervical smears: a feasibility study.
Ehehalt D, Lener B, Pircher H, Dreier K, Pfister H, Kaufmann AM, Frangini S, Ressler S, Müller-Holzner E, Schmitt M, Höfler D, Rostek U, Kaiser A, Widschwendter A, Zwerschke W, Jansen-Dürr P.
Journal of Clinical Microbiology. 2011 Nov 30. [Epub ahead of print]
30.11.2011
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, Lane SR, Zembryki D, Rubin SD, Winer EP.
Journal of Neuro-Oncology. 2011 Dec;105(3):613-20. Epub 2011 Jun 26.
26.11.2011
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R.
Lancet. 2011 Nov 12;378(9804):1707-16. Epub 2011 Oct 19.
19.10.2011
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, Greil R, Jelen A, Böhm G, Jasarevic Z, Haid A, Gruber C, Pöstlberger S, Filipits M, Gnant M.
Clinical Cancer Research. 2011 Oct 13. [Epub ahead of print]
13.10.2011
Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group.
Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A.
Journal of Clinical Oncology. 2011 Oct 11. [Epub ahead of print]
11.10.2011
Das RANK/RANK- Ligand- System beim Mammakarzinom: biologische Grundlagen.
Mlineritsch B, Ressler S, Greil R.
Universum Innere Medizin 10/11
10/2011
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.
Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M.
Journal of Cancer Research and Clinical Oncology. 2011 Sep 30. [Epub ahead of print]
30.09.2011
Bone marrow may be the preferable graft source in recipients homozygous for HLA-C group 2 ligands for inhibitory killer Ig-like receptors.
Clausen J, Kircher B, Auberger J, Schumacher P, Grabmer C, Mühlbacher A, Gastl G, Nachbaur D.
Bone Marrow Transplantion. 2011 Sep 26.
26.09.2011
Therapie der chronisch lymphatischen Leukämie (B-CLL).
Steinkirchner S, Egle A.
Universum Innere Medizin. 09/11.
09/2011
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial.
Fiegl M, Mlineritsch B, Hubalek M, Bartsch R, Pluschnig U, Steger GG.
BMC Cancer. 2011 Aug 24;11(1):373.
24.08.2011
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial.
Fiegl M, Mlineritsch B, Hubalek M, Bartsch R, Pluschnig U, Steger GG.
BMC Cancer. 2011 Aug 24;11:373.
24.08.2011
Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic Lymphocytic Leukemia Cells
Brachtl G, Sahakyan K, Denk U, Girbl T, Alinger B, Hofbauer SW, Neureiter D, Hofbauer JP, Egle A, Greil R, Hartmann TN.
PLoS One. 2011;6(8):e23758. Epub 2011 Aug 18.
18.08.2011
Allogeneic Bone Marrow versus Peripheral Blood Stem Cell Transplantation: A Long-Term Retrospective Single-Centre Analysis In 329 Patients.
Auberger J, Clausen J, Kropshofer G, Kircher B, Lindner B, Nachbaur D.
European Journal of Haematology. 2011 Aug 17. doi: 10.1111/j.1600-0609.2011.01692.x. [Epub ahead of print]
17.08.2011
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M.
Clinical Cancer Research. 2011 Aug 1.
01.08.2011
Lebermetastasen nach Trastuzumab adjuvant- was nun?
Mlineritsch B.
Universum Innere Medizin 8/11
08/2011
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R.
Lancet. 2011 Aug 27;378(9793):771-84. Epub 2011 Jul 28.
28.07.2011
Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia.
Stadlmayr A, Aigner E, Steger B, Scharinger L, Lederer D, Mayr A, Strasser M, Brunner E, Heuberger A, Hohla F, Steinwendner J, Patsch W, Datz C.
Journal of Internal Medicine. 2011 Jul;270(1):41-9. doi: 10.1111/j.1365-2796.2011.02377.x. Epub
2011 Apr 25.
07/2011
Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools.
Merkel O, Hamacher F, Sifft E, Kenner L, Greil R; for the European Research Initiative on Anaplastic Large Cell Lymphoma.
Molecular Cancer Therapeutics. 2011 Jun 28.
28.06.2011
Raltegravir in pregnancy: a case series presentation.
Taylor N, Touzeau V, Geit M, Gisinger M, Egle A, Greil R, Rieger A, Zangerle R.
Int J STD AIDS. 2011 Jun;22(6):358-60.
22.06.2011
Perinasal dermatitis due to a local plasmacytoma with vicinal nodular ALλ amyloi.
Laimer M, Namberger K, Abonour R.
Amyloid. 2011 Jun;18 Suppl 1:98-100.
18.06.2011
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P,Hochreiner G, Forsthuber EP, Fesl C, Greil R; on behalf of the Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
Lancet Oncol. 2011 Jun 3. [Epub ahead of print]
03.06.2011
ASH Report. Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010.
Melchardt T, Hofbauer SW, Greil R, Hopfinger G.
Memo - Magazine of European Medical Oncology. 2011 June 1; 4(2): 120-123.
01.06.2011
Jahrestagung DGHO, ÖGHO und SGMO:
NHL und CLL
Hopfinger G
JATROS Haematologie und Onkologie 6/2011
06/2011
Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.
Hofbauer JP, Heyder C, Denk U, Kocher T, Holler C, Trapin D, Asslaber D, Tinhofer I, Greil R, Egle A.
Leukemia. 2011 Sep;25(9):1452-8. doi: 10.1038/leu.2011.111. Epub 2011 May 24.
24.05.2011
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Grundbichler M, Mlineritsch B, Ressler S, Moik M, Kappacher A, Rosenlechner S, Greil R.
Oncology. 2011;80(1-2):34-41. Epub 2011 May 23.
23.05.2011
Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.
Weiss L, Melchardt T, Egle A, Grabmer C, Greil R, Tinhofer I.
Cancer. 2011 May 15;117(10):2163-9. doi: 10.1002/cncr.25752. Epub 2010 Nov 18
15.05.2011
Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial.
Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Pöstlberger S, Steger GG, Seifert M, Dubsky P, Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M.
J Clin Oncol. 2011 Jul 1;29(19):2653-9. Epub 2011 May 9.
09.05.2011
Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G, Namberger K, Witt V, Schloegl E, Zojer N, Linkesch W, Kalhs P, Greinix HT.
Transfusion. 2011 May;51(5):968-75. doi: 10.1111/j.1537-2995.2010.02896.x. Epub 2010 Sep 28.
05/2011
Wechselbeschwerden unter antihormoneller oder Chemotherapie bei Brustkrebs.
Pircher M, Mlineritsch B, Greil R.
Med.ium. 05/2011
05/2011
Combination Therapy of Lapatinib and Capecitabine forErbB2-Positive Metastatic or Locally Advanced BreastCancer: Results from the Lapatinib Expanded AccessProgram (LEAP) in Central and Eastern Europe.
Greil R, Borštnar S, Petráková K, Marcou Y, Pikiel J, Wojtukiewicz MZ, Koza I, Steger GG, Linn M, Das Gupta A, Cwiertka K.
Onkologie. 2011;34(5):233-8. Epub 2011 Apr 26.
26.04.2011
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.
Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, Marosi C, Ochsenbein A, Pichler J, Roelcke U, Weder P, Zander T, Wick W, Weller M.
Acta Oncologica. 2011 Apr 18. [Epub ahead of print]
18.04.2011
Chronische Lymphatische Leukämie (CLL) – Wann gilt das Konzept „watch & wait“ noch?
Egle A, Steinkirchner S.
Universum Innere Medizin. 04/11.
04/2011
Rheuma, Schwangerschaft und Biologika.
Studnicka-Benke A.
JATROS Orthopädie. April 2011.
04/2011
VEGF, PARP, mTOR, EGFR und PI3K beim HER2-negativen Mammakarzinom.
Gampenrieder S, Mlineritsch B, Greil R.
Universum Innere Medizin. 04/11.
04/2011
Wie verändere ich mein Äußeres zum Positiven?
Eder S, Mlineritsch B, Greil R.
Med.ium. April 2011.
04/2011
Sentinel Node Biopsy After Primary Chemotherapy in Breast Cancer: A Note of Caution from Results of ABCSG-14.
Tausch C, Steger GG, Haid A, Jakesz R, Fridrik MA, Reitsamer R, Pöstlberger S, Lang A, Gnant M, Greil R.
The Breast Journal. 2011 Mar 31. doi: 10.1111/j.1524-4741.2011.01073.x.
31.03.2011
Current evidence for the treatment of invasive fungal infections in immunocompromised patients.
Auberger J, Lass-Flörl C.
Clinical Investigation. Mar 2011, 1(3): 447-457.
03/2011
ÖGHO-Frühjahrstagung: Bendamustin-
Breite Aktivität bei Neoplasien des lymphopoetischen Systems
Hopfinger G
JATROS Haematologie und Onkologie 3/2011
03/2011
Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.
Fiegl M, Falkner F, Steurer M, Zojer N, Hopfinger G, Haslbauer F, Winder G, Voskova D, Andel J, Lang A, Brychtova Y, Mayer J, Greil R, Gastl G; for The Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL.
Annals of Hematology. 2011 Feb 25. [Epub ahead of print]
25.02.2011
Lang anhaltende Remission bei Brustkrebs und Lebermetastasen – Fallbericht.
Mlineritsch B.
Krebs:Hilfe. 2:2011
02/2011
Lang anhaltende Remission bei Brustkrebs und Lebermetastasen.
Mlineritsch B.
Krebs:Hilfe. Sonderdruck 2:2011
02/2011
Preoperative Oxaliplatin, Capecitabine, and External Beam Radiotherapy in Patients with Newly Diagnosed, Primary Operable, cT(3)NxM0, Low Rectal Cancer : A Phase II Study.
Ofner D, Devries AF, Schaberl-Moser R, Greil R, Rabl H, Tschmelitsch J, Zitt M, Kapp KS, Fastner G, Keil F, Eisterer W, Jäger R, Offner F, Gnant M, Thaler J; TAKO 05/ABCSG R-02 Trial Investigators the Investigators.
Strahlentherapie und Onkologie. 2011 Jan 21. [Epub ahead of print]
21.01.2011
Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.
Resch G, Schaberl-Moser R, Kier P, Kopetzky G, Scheithauer W, Sliwa T, Greil R, Nösslinger T, Mayrbäurl B, Thaler J.
Annals of Oncology. 2011 Feb;22(2):486-7. Epub 2011 Jan 13.
13.01.2011
Subcellular localization of the human papillomavirus 16 E7 oncoprotein in CaSki cells and its detection in cervical adenocarcinoma and adenocarcinoma in situ.
Dreier K, Scheiden R, Lener B, Ehehalt D, Pircher H, Müller-Holzner E, Rostek U, Kaiser A, Fiedler M, Ressler S, Lechner S, Widschwendter A, Even J, Capesius C, Jansen-Dürr P, Zwerschke W.
Virology. 2011 Jan 5;409(1):54-68. Epub 2010 Oct 23.
05.01.2011
48-jähriger Patient mit fokal fortgeschrittenem, distalem Ösophaguskarzinom - Beispiel einer geglückten
interdisziplinären Zusammenarbeit.
Hohla F, Vaszi A, Datz L, Rettenbacher L, Hutter J.
Tumorboard - Onkologie aus multidisziplinärer Sicht. 2011; 1 (1), 27-30.
01/2011
Brustkrebsrisiko und Vorsorge.
Mlineritsch B.
Med.ium. Jänner/Februar 2011, S 36-38.
01/2011
CLL-Therapie: Die tägliche Praxis.
Egle A
Krebs:Hilfe. 1:2011
01/2011
Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.
Gassner FJ, Weiss L, Geisberger R, Hofbauer JP, Egle A, Hartmann TN, Greil R, Tinhofer I.
Cancer Immunol Immunother. 2011 Jan;60(1):75-85. Epub 2010 Sep 21.
01/2011
mTOR-Inhibition bei Brustkrebs – Überwindung der endokrinen Resistenz?
Mlineritsch B.
SPECTRUM Onkologie. 1/2011 S33-35.
01/2011
Xeloda® (Capecitabin) – Zeitgemäße Chemotherapie des Mammakarzinoms.
Mlineritsch B.
SPECTRUM Onkologie. 1/2011 S. 47.
01/2011
„Krebskranke stehen mitten im Leben“ - Interview.
Greil R.
Med.ium. Jänner/Februar 2011, S 36-38.
01/2011
A new trisaccharide derivative from Prenanthes purpurea.
Posch M, Jöhrer K, Sezai Cicek S, Greil R, Ellmerer E, Zidorn C.
J SERB CHEM SOC, 76 (6) 841-845 (2011), JSCS-4164
2011
Bisphosphonate in der Therapie des Mammakarzinoms.
Ressler S, Mlineritsch B und Greil R.
Med.ium (03): 26-30.
2011
Clinical aspects of 2009 pandemic influenza A (H1N1) virus infection in Austria.
Poeppl W, Hell M, Herkner H, Stoiser B, Fritsche G, Schurz-Bamieh N, Poeppl G, Gattringer R, Jones N, Maass M, Egle A, Burgmann H.
Infection. 2011 Aug;39(4):341-52. Epub 2011 May 5.
2011
CLL-News aus London
Melchardt T, Hopfinger G.
JATROS Haematologie und Onkologie.
2011
Complete Remission of Waldenstrom Macroglobulinemia With Azacitidine and Rituximab.
Weiss L, Melchardt T, Neureiter D, Kemmerling R, Pleyer L, Greil R, Egle A, Moshir S.
J Clin Oncol. 2011 Jul 5. [Epub ahead of print]
2011
Oxaliplatin, Irinotecan and Cetuximab in Advanced Gastric Cancer. A Multicenter Phase II Trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
Wöll E, Greil R, Eisterer W, Bechter O, Fridrik MA, Grünberger B, Zabernigg A, Mayrbäurl B, Russ G, Dlaska M, Obrist P, Thaler J.
Anticancer Research. 2011 Dec;31(12):4439-43.
2011
PARP-Inhibitoren.
Ressler S, Mlineritsch B, Greil R.
Universum Innere Medizin. 04/11
2011
Teilpatentschutz und Off-Label-Use: am Beispiel des Mammakarzinoms.
Mlineritsch B.
MEDahead FACTS & FIGURES
2011
Zoledronic acid for adjuvant use in patients with breast cancer.
Ressler S, Mlineritsch B, Greil R.
Expert Review of Anticancer Therapy. 2011 Mar;11(3):333-49.
2011
2010
MicroRNAs as biomarkers for the diagnosis and prognosis of human cancer.
Asslaber D, Pinon Hofbauer J, Greil R, Egle A.
Journal of Nucleic Acids Investigations. 2010, Dec 1, 1(1): 76-80.
01.12.2010
Chronic Myeloid Leukemia (CML).
Pleyer L., von Bubnoff N., Neureiter D., Faber V. and Duyster J.
In Greil R., Pleyer L., Neureiter D., Faber V.(Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (S. 117-152). Wien New York: Springer. ISBN 978-3-211-79891-1.
12/2010
The impact of storage effects in biobanks on biomarker discovery in systems biology studies.
Balasubramanian R, Müller L, Kugler K, Hackl W, Pleyer L, Dehmer M, Graber A.
Biomarkers. 2010 Dec;15(8):677-83. Epub 2010 Oct 5.
12/2010
Alemtuzumab (MabCampath®) – Wirksame Waffe in der Kombinationstherapie.
Egle A.
SPECTRUM Onkologie. 4/10, S. 88.
10/2010
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S.
Journal of the National Cancer Institute. Monogr. 2010;2010(41):162-77.
10/2010
Differenzierte Therapieansätze beim myelodysplastischen Syndrom.
Steinkirchner S, Melchardt T, Egle A.
JATROS Haematologie und Onkologie. 2010 Sep 20.
20.09.2010
Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells.
Desch P, Asslaber D, Kern D, Schnidar H, Mangelberger D, Alinger B, Stoecher M, Hofbauer SW, Neureiter D, Tinhofer I, Aberger F, Hartmann TN, Greil R.
Oncogene. 2010 Sep 2;29(35):4885-95. Epub 2010 Jul 5.
02.09.2010
Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial.
Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A.
Journal of Clinical Oncology. 2010 Aug 16. [Epub ahead of print]
16.08.2010
Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma.
Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V.
New England Journal of Medicine. 2010 Aug 12;363(7):640-652.
12.08.2010
Evidence for the conversion of docetaxel into 7'-epidocetaxel in patients receiving Taxotere((R))-based conventional chemotherapy.
Czejka M, Greil R, Ulsperger E, Schnait H, Kienesberger K, Brumnik T, Farkouh A, Schierholz J.
International Journal of Clinical Pharmacology and Therapeutics. 2010 Jul;48(7):483-4. No abstract available.
08/2010
Aminoglykoside - Eine tote Substanzklasse?
Egle A.
JATROS Infektiologie. Jahrgang 4, Juli, 2/2010
07/2010
Erforschung der Chronisch Lymphatischen Leukämie am LIMCR.
Hartmann TN.
Med.ium. 6/2010.
06/2010
Focus Onkologie: Neues beim Follikulären Lymphom.
Egle A.
Universum Innere Medizin. 06/2010.
06/2010
microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.
Asslaber D, Piñón JD, Seyfried I, Desch P, Stöcher M, Tinhofer I, Egle A, Merkel O, Greil R.
Blood. 2010 May 27;115(21):4191-7. Epub 2010 Jan 20.
27.05.2010
ÖGHO-Frühjahrstagung: Chronische Lymphatische Leukämie, Adhäsionsmoleküle als mögliche therapeutische Ziele.
Hartmann TN.
JATROS Haematologie und Onkologie. 3/2010, Seite 63-65.
03/2010
B-CLL: Datenfülle zu Pathophysiologie und klinischem Management.
Egle A.
JATROS Haematologie und Onkologie. 01/2010, Seite 80-82.
01/2010
1-Liposomal cytarabine is effective and tolerable in the treatment of CBS relapse of acute lymphoblastic leukemia (ALL) and very aggressive lymphoma.
Gökbuget N, Hartog M, Bassan R, Coiffier B, Derigs HG, Dombret H, Greil R, Huguet F, Jourdan E, Junghanss C, Leimer L, Pollmeier G, Reichle A, Ribera J, Schmid M, Serve H, Stelljes M, Stuhlmann R, Hoelzer D for the German Multicenter Study Group of Adult ALL and the European Working Group on Adult ALL.
Haematologica-The Hematology Journal. 2010 in the press.
2010
A correlation of endocrine and anticancer effects of some antagonists of GHRH.
Kovács M, Schally AV, Hohla F, Rick FG, Pozsgai E, Szalontay L, Varga JL, Zarándi M.
Peptides. 2010 Jul 13. [Epub ahead of print]
2010
Aktuelle Therapie indolenter Non-Hodgkin-Lymphome.
Melchardt T, Egle A
Krebs:Hilfe. 3/2010, Seite 10-12.
2010
An uncommon cause of anaemia: Sheehan's syndrome.
Melchardt T, Namberger K, Weiss L, Egle A, Faber V, Greil R.
Wiener Klinische Wochenschrift. 2010 Dec 7.
2010
Aplasiestation der III. Medizin.
Russ G, Greil R
Med.ium. 05/2010, Seite 23-24.
2010
Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation.
Labi V, Erlacher M, Krumschnabel G, Manzl C, Tzankov A, Pinon J, Egle A, Villunger A.
Genes & Development. 2010 Aug 1;24(15):1602-7.
2010
BEVACIZUMAB 8avastin® - Blick in die Zukunft
Mlineritsch B
Krebs:Hilfe 5:2010
2010
Bewegung gegen Krebs.
Pleyer L., Kappacher A., Rosenlechner S., Greil R.
In Braumann KM., Stilller N. (Editors), Bewegungstherapie bei internistischen Erkrankungen (S. 223-240).Berlin: Springer (2010)
2010
Bewegungstherapie bei internistischen Erkrankungen
Pleyer L, Kappacher A, Rosenlechner S, Greil R.
Bewegung und Krebs, 2010, II, 223-240, DOI: 10.1007/978-3-642-01332-4_17
2010
Bone-Health Management unter Aromatasehemmern beim Mammakarzinom.
Mlineritsch B
SPECTRUM Osteoporose. 01/2010 Seite 49-50.
2010
CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B.
Leick M, Catusse J, Follo M, Nibbs RJ, Hartmann TN, Veelken H, Burger M.
Immunology. 2010 Apr;129(4):536-46. Epub 2009 Dec 2.
2010
Chronic Myeloid Neoplasias and Clonal Overlap Syndromes
Greil R., Pleyer L., Neureiter D., Faber V.
Wien New York: Springer, (2010)
2010
Chronic Myelomonocytic Leukemia (CMML).
Pleyer L., Neureiter D., Faber V. and Greil R.
In Greil R., Pleyer L., Neureiter D., Faber V.(Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (S. 223-234). Wien New York: Springer
2010
Chronisch Lymphatische Leukämie im Überblick.
Greil R
krebspatienten.info
2010
Clonal Bone Marrow Failure Overlap Syndromes.
Pleyer L., Neureiter D. and Greil R.
In Greil R., Pleyer L., Neureiter D., Faber V.(Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (S. 281-288). Wien New York: Springer
2010
De novo “Classic” Paroxysmal Nocturnal Hemoglobinuria (PNH) (Marchiafava-Micheli Syndrome).
Pleyer L. and Greil R.
In Greil R., Pleyer L., Neureiter D., Faber V.(Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (S. 259-280). Wien New York: Springer
2010
Die Mammacarcinom- Spezialistin.
Mlineritsch B
Med.ium. S 12, 16.08.2010
2010
Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.
Fridrik MA, Hausmaninger H, Lang A, Drach J, Krieger O, Geissler D, Michlmayr G, Ulsperger E, Chott A, Oberaigner W, Greil R.
Annals of Hematology. 2010 Mar;89(3):273-82. Epub 2009 Aug 20.
2010
Eierstockkrebs.
Mlineritsch B
krebspatienten.info
2010
Essential Thrombocythemia (ET).
Pleyer L., Faber V., Neureiter D. and Greil R.
In Greil R., Pleyer L., Neureiter D., Faber V. (Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (S. 14-50). Wien New York: Springer (2010)
2010
HIV-Behandlungszentrum.
Taylor N.
Med.ium. 3/2010.
2010
Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M, Egger G, Hassler MR, Thallinger C, Schmatz A, Turner SD, Greil R, Kenner L.
Proceedings of the National Academy of Sciences of the United States of America. 2010 Aug 30.
2010
Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.
Merkel O, Asslaber D, Piñón JD, Egle A, Greil R.
Cell Cycle. 2010 Jul 15;9(14):2764-8. Epub 2010 Jul 3.
2010
Introduction to „Classic“ Chronic Myeloproliferative Disoderes (CMPDs)- Molecular and Cellular Biology.
Pleyer L. and Greil R.
In Greil R., Pleyer L., Neureiter D., Faber V. (Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes
(S. 1-15). Wien New York: Springer
(2010)
2010
Krebsmedikamente im Focus.
Gastl G, Samonigg H, Ludwig H., Greil R
krebspatienten.info
2010
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig H, Adam Z, Hajek R, Greil R, Tóthová E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N.
Journal of Clinical Oncology. 2010 Oct 20;28(30):4635-41. Epub 2010 Sep 7.
2010
Modifying Akt signaling in B-cell chronic lymphocytic leukemia cells.
Hofbauer SW, Piñón JD, Brachtl G, Haginger L, Wang W, Jöhrer K, Tinhofer I, Hartmann TN, and Greil R.
Cancer Research. 2010 Sep 7. [Epub ahead of print]
2010
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C, Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R.
British Journal of Cancer. 2010 Oct 12;103(8):1201-8. Epub 2010 Sep 28.
2010
Myelodysplastic Syndromes (MDS).
Pleyer L., Neureiter D., Faber V. and Greil R.
In Greil R., Pleyer L., Neureiter D., Faber V.(Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (S. 153-222). Wien New York: Springer
2010
Nebenwirkung von Lapatinib.
Ressler S und Mlineritsch B.
Krebs:Hilfe. 2/2010
2010
Nebenwirkungen von Azacitidin.
Melchardt T, Mlineritsch B, Greil R
Krebs:Hilfe. Krebshilfe 02/2010, Seiten 12-13.
2010
Nebenwirkungen von Bortezomib.
Weiss L, Mlineritsch B, Greil R
CliniCum. 02/2010.
2010
Nebenwirkungen von Pazopanib, Sorafenib und Sunitinib.
Petru E, Mlineritsch B, Luschi G.
CliniCum. 02/2010.
2010
Neue "targeted therapies" jenseits von Trastuzumab und Becacizumab.
Mlinertisch B
JATROS Haematologie und Onkologie. 01/2010, Seite 72-73.
2010
Neue Therapie in Sicht.
Merkel O, Kenner L, Greil R
SpringerMedizin. 22.09.2010
2010
Neues bei follikulären Lymphomen.
Steinkirchner S, Egle A.
Universum Innere Medizin. 10/2010
2010
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators.
New England Journal of Medicine. 2010 Jun 17;362(24):2251-9. Epub 2010 Jun 5.
2010
PLZF/ZBTB16, a glucocorticoid response gene in acute lymphoblastic leukemia, interferes with glucocorticoid-induced apoptosis.
Wasim M, Carlet M, Mansha M, Greil R, Ploner C, Trockenbacher A, Rainer J, Kofler R.
Journal of Steroid Biochemistry and Molecular Biology. 2010 Jun;120(4-5):218-27. Epub 2010 May 6.
2010
Polycythemia Vera (PV).
Pleyer L.,Neureiter D. and Greil R.
In Greil R., Pleyer L., Neureiter D., Faber V. (Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (S. 51-80). Wien New York: Springer
2010
PRIMA-Studie mit dem Anti-CD20-Antikörper Rituximab als Erhaltungstherapie – Neues beim follikulären Lymphom.
Steinkirchner S, Egle A.
Universum Innere Medizin. 06/10.
2010
Primary Myelofibrosis (PMF)
Pleyer L., Faber V., Neureiter D. and Greil R.
[Previously Chronic Idiopathic Mylofibrosis (CIMF), Myelofibrosis with Myeloid Metaplasia (MMM), Agnogenic Myeloid Metaplasia (AMM)]. (S. 81-116). Wien New York: Springer
2010
Qigong und Lebensqualität bei Krebs.
Wendtner F.
Qigong Periodikum. Nummer 29.2/2010
2010
Rare Clonal Myeloid Disease.
Melchardt T., Weiss L., Pleyer L., Neureiter D., Faber V. and Greil R.
In Greil R., Pleyer L., Neureiter D., Faber V.(Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes (S. 235-258). Wien New York: Springer
2010
Recent developments in the treatment of peripheral T-cell lymphoma.
Hopfinger G, Weit N, Herling M.
Magazine of European Medical Oncology. 2010;3:73–76.
2010
Riding the 2-edged sword.
Egle A.
Blood. 2010 Jun 3;115(22):4325-6. Comment.
2010
SABCS: „neue targeted therapies“ jenseits von Trastuzumab und Bevacizumab.
Mlineritsch B
Universimed. 08.März, 2010.
2010
Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.
Hohla F, Buchholz S, Schally AV, Krishan A, Rick FG, Szalontay L, Papadia A, Halmos G, Koster F, Aigner E, Datz C, Seitz S.
Cancer Letters. 2010 Aug
1;294(1):35-42. Epub 2010 Feb 13.
2010
Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer.
Hohla F, Schally AV.
Cell Cycle. 2010
May;9(9):1738-41. Epub 2010 May 29.
2010
The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients.
Perkhofer S, Lass-Flörl C, Hell M, Russ G, Krause R, Hönigl M, Geltner C, Auberger J, Gastl G, Mitterbauer M, Willinger B, Knöbl P, Resch G, Waldner R, Makrai A, Hartmann G, Girschikofsky M, Greil R.
International Journal of Antimicrobial Agents. 2010 Oct 12.
2010
Therapiestrategien beim triple-negativen Mammakarzinom.
Ressler S
SPECTRUM Onkologie. 2/2010, Seite 88-90.
2010
Triple Negative Breast Cancer
Ressler S, Mlineritsch B, Greil R.
memo - Magazine of European Medical Oncology. Volume 3, Number 4, 185-189, DOI: 10.1007/s12254-010-0232-5
2010
Triple-negatives Mammakarzinom – Aktueller Stand
Ressler S
JATROS Haematologie und Onkologie. 3/2010, Seite 46-50.
2010
Zielgerichtete Krebstherapie des Mammacarcinoms.
Mlineritsch B, Kappacher K.
Salzburger Arzt. 10/2010
2010
2009
Is Higher Efficacy Always at the Price of More Side Effects during Chemotherapy?
Mlineritsch B.
Breast Care. 2009;4(3):162-165. Epub 2009 Jun 23.
23.06.2009
Implementation of evidence based medicine in primary care.
Rinnerberger A, Grafinger M, Melchardt T, Sönnichsen A.
Wiener Medizinische Wochenschrift. 02/2009; 159(7-8):207-10.
04/2009
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Poestlberger S, Menzel C, Jakesz R, Kubista E/Seifert M, Marth C, Samonigg H, Bjelic-Radisic V, Tausch C, Steger G, Greil R, on behalf of the Austrian Breast and Colorectal Cancer Study Group
New England Journal of Medicine. Feb 12;360(7):679-91
2009
Bewegung gegen Krebs - Lebensstilambulanz für Krebspatienten.
Mlineritsch B, Berer A, Greil R.
Der Salzburger Arzt , 2009 Mai, 16-19
2009
Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymphnodes and bone marrow.
Hartmann T, Grabovsky V, Wang W, Desch P, Rubenzer G, Wollner S, Binsky I, Vallon-Eberhard A, Sapoznikov A, Haran M, Shachar I, Burger M, Honczarenko M, Greil R, Alon R.
Cancer Research. 2009 Apr 1;69(7):3121-30. Epub 2009 Mar 17.
2009
Die Bedeutung von JAK2 in der Pathogenese
Pleyer L, Greil R
JATROS, 05/2009, Seite 26-30
2009
Die Palliativstation an der III Medizin.
Faber V, Greil R.
Salzburger Arzt. 11/2009. Seite 24-26.
2009
Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease.
Tinhofer I, Weiss L, Gassner F, Rubenzer G, Holler C, Greil R.
Journal of Immunotherapy. 2009 Apr;32(3):302-9.
2009
GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.
Hohla F, Buchholz S, Schally AV, Seitz S, Rick FG, Szalontay L, Varga JL, Zarandi M, Halmos G, Vidaurre I, Krishan A, Kurtoglu M, Chandna S, Aigner E, Datz C.
Cell Cycle. 2009 Oct 1;8(19):3149-56. Epub 2009 Oct 3.
2009
HER2/neu- neue Wege, Neue Ziele
Mlinertisch B
JATROS 04/2009, Seite 26-38
2009
Her2/neu-neue Wege, neue Ziele
Mlineritsch B
SpringerMedizin.at 04/2009
2009
HIV-Patienten mit Gedächtnisstörung; Die Optimierung einer ZNS-wirksamen HAART steht im Vordergrund
Taylor N
Ärztemagazin Ausgabe 45/2009, Seite16-17
2009
Hodgkin lymphoma in Tyrol - a population-based study.
Fong D, Steurer M, Greil R, Gunsilius E, Spizzo G, Gastl G, Tzankov A.
Annals of Hematology. 2009 May;88(5):449-56. Epub 2008 Oct 10.
2009
Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals.
Taylor N, Schmid I, Egle A, Greil R, Patsch W, Oberkofler H.
Antiviral Therapy. 2009;14(8):1189-93.
2009
Insulin-like growth factor-binding protein-3 in osteosarcomas and normal bone tissues.
Ressler S, Radhi J, Aigner T, Loo C, Zwerschke W, Sergi C.
Anticancer Res. 2009 Jul;29(7):2579-87.
2009
Iron stores, liver transaminase levels and metabolic risk in healthy teenagers.
Aigner E, Hinz C, Steiner K, Rossmann B, Pfleger J, Hohla F, Steger B, Stadlmayr A, Patsch W, Datz C.
European Journal of Clinical Investigation. 2010 Feb;40(2):155-63. Epub 2009 Dec 27.
2009
Kausale Therapie der Opioid-induzierten Obstipation.
Faber V.
Arzt + Patient. 2/2009 (28), Interview.
2009
Klassische myeloproliferative Erkrankungen: Die Bedeutung von JAK2 in der Pathogenese.
Pleyer L, Greil R
JATROS Haematologie und Onkologie 05/2009 (Pleyer L, Greil R)
2009
Klinik und Labor verbinden
Greil R
Österreichische Ärztezeitung, Nr. 7, 10.04.2009
2009
Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF; Austrian Breast and Colorectal Cancer Study Group.
Clinical Cancer Research. 2009 Sep 15;15(18):5888-94. Epub 2009 Sep 1.
2009
Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
Gnant M, Dubsky P, Fitzal F, Blaha P, Schoppmann S, Steger G, Marth C, Samonigg H, Hüttner K, Fohler H, Ruecklinger E, Jakesz R, Greil R; Austrian Breast and Colorectal Cancer Study Group.
Clinical Breast Cancer. 2009 Jun;9 Suppl 1:S18-27. Review.
2009
Mature T-cell malignancies: a diagnostic and therapeutic challenge.
Hopfinger G and Herling M.
Magazine of European Medical Oncology. 2009;2:134-41.
2009
MDS - Krankheitsmodifizierende Therapieformen.
Egle A.
JATROS Haematologie und Onkologie. 2/2009 (S. 61 - 63).
2009
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer.
Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roché H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP.
Clinical Cancer Research. 2009 Feb 15;15(4):1452-1459.
2009
Multicenter Phase II study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First line Treatment in Elderly Patients with Metastatic Breast Cancer.
Mlineritsch B, Schabel-Moser R, Andel J, Fridrik M, Moik M, Mayer P, Russ G, Rass C, Greil R, on behalf of the Arbeitsgemeinschaft medikamentöse Tumortherapie Study Group (AGMT).
Onkologie. 2009;32(1-2):18-24. Epub 2009 Jan 20.
2009
Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: efficacy and safety in a phase II pilot study.
Greil R, Moik M, Reitsamer R, Ressler S, Stoll M, Namberger K, Menzel C, Mlineritsch B.
EJSO - European Journal of Surgical Oncology. 2009 Feb 26. [Epub ahead of print]
2009
Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.
Hartmann TN, Pleyer L, Desch P, Egle A, Greil R.
Discovering Medicine. 2009 Oct;8(42):157-64. Review.
2009
Palliative Chemotherapie des Mammakarzinoms
Mlineritsch B
SPECTRUM Onkologie, 4/2009, Seite 22-25
2009
Phase II randomized neoadjuvant study of the mTOR inhibitor everolimus (RAD001) in combination with letrozole versus placebo and letrozole in patients with ER+ breast cancer
Baselga J, Semiglazov V, von Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, KubistaE, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane H, Dixon JM, Jonat W, Rugo HS
Journal of Clinical Oncology. 2009 Jun 1;27(16):2630-7. Epub 2009 Apr 20.
2009
PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.
Holler C, Piñón JD, Denk U, Heyder C, Hofbauer S, Greil R, Egle A.
Blood. 2009 Mar 19;113(12):2791-4. Epub 2009 Jan 23.
2009
Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
Seitz S, Schally AV, Treszl A, Papadia A, Rick F, Szalontay L, Szepeshazi K, Ortmann O, Halmos G, Hohla F, Buchholz S.
Anticancer Drugs. 2009 Aug;20(7):553-8.
.
2009
Psychoonkologie an der III. Medizin
Rambause-Martinek L, Wendtner F, Greil R
Salzburger Arzt, 12/2009, Seite 20-22
2009
Randomized Phase III Trial Comparing Biweekly Infusional 5-Fluouracil/Leucovorin Alone or with Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3.
Van Cutsem E, Labianca R, Bodoky G, Barone C, Roth A, Aranda E, Nordlinger B, Topham C, Tabernero J, André T, Sobrero A, Mini E, Greil R, Di Constanzo F, Colette L, Cisar L, Zhang X, Kayat D, Bokemeyer C, Roth AD, Cunningham D.
Journal of Clinical Oncology. 2009 Jul 1;27(19):3117-25. Epub 2009 May 18.
2009
Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment.
Aigner E, Bachofner N, Klein K, De Geyter C, Hohla F, Patsch W, Datz C.
Journal of Clinical Endocrinology & Metabolism. 2009 Apr;94(4):1229-35. Epub 2009 Jan 21.
2009
Rheumatoide Arthritis.
Psenak O, Studnicka-Benke A, Greil R.
Salzburger Arzt. 22. Jahrgang, Nummer 7/8, Juli/August 2009, S. 17-21.
2009
Stammzellen: Die Kernreaktoren für das Tumorfeuer
Greil R
Österreichische Ärztezeitung 25.05.2009
2009
Stammzelltransplantation.
Namberger K , Greil R
Salzburger Arzt. 12/2009
2009
Technologien der Stammzellgewinnung
Namberger K , Greil R
Krebs:hilfe Heft 6:2009
2009
Thalidomide-Dexamethasone compared to Melphalen-prednisolone in elderly patients with Multiple Myeloma.
Ludwig H, Hajek R, Tóthová E, Johannes Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, Kuhn I, Zojer N, Hinke A.
Blood. 2009 Apr 9;113(15):3435-42.
2009
The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer.
Bartsch R, Mlineritsch B, Gnant M, Niernberger T, Pluschnig U, Greil R, Wenzel C, Sevelda P, Thaler J, Rudas M, Pober M, Zielinski CC, Steger GG; Austrian Fulvestrant Registry.
Breast Cancer Research and Treatment. 2009 May;115(2):373-80. Epub 2008 Jul 26.
2009
The Dark Side of the Moon - The Side Effects of Therapy in a Dynamic Era of Breast Cancer Management.
Greil R.
Breast Care. 2009; 4:144-147, Editorial.
2009
The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells.
Nevo I, Sagi-Assif O, Meshel T, Ben-Baruch A, Jöhrer K, Greil R, Trejo LE, Kharenko O, Feinmesser M, Yron I, Witz IP.
Cancer Letters. 2009 Jan 8;273(1):127-39. Epub 2008 Sep 7.
2009
The molecular and cellular biology of chronic lymphocytic leukemia as the basis for novel therapeutic approaches.
Pleyer L, Egle A, Hartmann TN, Greil R.
Nature Clinical Practice Oncology. 2009 Jul;6(7):405-18. Epub 2009 Jun 2. Review.
2009
Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition.
Köster F, Engel JB, Schally AV, Hönig A, Schröer A, Seitz S, Hohla F, Ortmann O, Diedrich K, Buchholz S.
Breast Cancer Res Treat. 2009 Jul;116(2):273-9. Epub 2008 Jul 16.
2009
Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition.
Buchholz S, Seitz S, Schally AV, Engel JB, Rick FG, Szalontay L, Hohla F,
Krishan A, Papadia A, Gaiser T, Brockhoff G, Ortmann O, Diedrich K, Köster F.
International Journal of Cancer. 2009 Oct;35(4):789-96.
2009
Update Glioblastom.
Mlineritsch B
SpringerMedizin. 09/2009.
2009
Vermeidung und Behandlung von Infekten bei PatientenInnen mit multiplem Myelom
Mlineritsch B
Magazin NHL, März 2009 (Seite 11-12)
2009
Vermeidung und Behandlung von Infekten bei PatientenInnen mit multiplem Myelom.
Mlineritsch B.
Mmagazin NHL, März 2009 (11-12)
2009
Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema.
Laimer M, Namberger K, Massone C, Koller J, Emberger M, Pleyer L, Hintner H, Greil R.
Acta Dermato-Venereologica. 2009 Nov;89(6):631-5.
2009
Zielgerichtete Krebstherapien; Antikörpertherapie des metastasierten Kolorektalen Karzinoms.
Mlineritsch B, Kappacher A, Greil R.
Salzburger Arzt. 10/2009, Seite 19-22.
2009
2008
A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells.
Hartmann TN, Grabovsky V, Pasvolsky R, Shulman Z, Buss EC, Spiegel A, Nagler A, Lapidot T, Thelen M, Alon R.
Journal of Leukocyte Biology. 2008 Oct; 84(4): 1130-40.
2008
A phase I/II study of bortezomib and capezitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Schmid P, Kuehnhardt D, Kiewe P, Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J, Niederle N, Brossart P, Freier W, Kümmel S, Van de Velde H, Regierer A, Possinger K.
Annals of Oncology. 2008 May;19(5): 871-6. Epub 2008 Jan 21.
2008
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Lancet Oncology. 2008 Sep;9(9):840-9. Epub 2008 Aug 19.
2008
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M; Austrian Breast and Colorectal Cancer Study Group.
Clinical Cancer Research. 2008 Apr 1;14(7):2082-7.
2008
Arsenic Trioxide induces apoptosis preferably in B-CLL cells of high risk patients including del17p13.
Merkel O, Heyder C, Asslaber D, Hamacher H, Holler C, Stöcher M, Tinhofer I, Greil R.
Journal of Molecular Medicine-JMM. 2008 May;86(5):541-52. Epub 2008 Feb 23.
2008
Basidiomycete metabolites attenuate virulence properties of Candida albicans in vitro.
Falkensammer B, Pleyer L, Ressler S, Berg A, Borg-von-Zepelin M, Nagl. M, Lass-Flörl C, Speth C, Dierich MP, Würzner R.
Mycoses. 2008 Nov;51(6):505-14. Epub 2008 Apr 16.
2008
Bim and Bmf in tissue homeostasis and malignant disease.
Piñon JD, Labi V, Egle A, Villunger A.
Oncogene. 2008 Dec;27 Suppl 1:S41-52. Review.
2008
Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT).
Wöll E, Kühr T, Eisterer W, Gattringer K, Greil R, Zabernigg A, Hilbe W, Thaler J.
Anticancer Research. 2008 Sep-Oct;28(5B):2901-5.
2008
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG; VISTA Trial Investigators.
New England Journal of Medicine. 2008 Aug 28;359(9):906-17.
2008
Capecitabin (Xeloda) - Wirksam beim metastasierten Mammakarzinom.
Greil R.
Krebshilfe. 5:2008 Seite /7
2008
Chronisch lymphatische Leukämie (CLL)-Auf dem Weg zur heilbaren Erkrankung
Egle A
Spectrum Onkologie 04/08
2008
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Sonneveld P, Hajek R, Nagler A, Spencer A, Bladé J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ; DOXIL-MMY-3001 Study Investigators.
Cancer. 2008 Apr 1;112(7):1529-37.
2008
Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease.
Aigner E, Theurl I, Haufe H, Seifert M, Hohla F, Scharinger L, Stickel F, Mourlane F, Weiss G, Datz C.
Gastroenterology. 2008 Aug;135(2):680-8. Epub 2008 Apr 15.
2008
Cyclin D1 expression in breast cancer and tamoxifen therapy.
Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W., Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant M, Filipits M, for the Austrian Breast and Colorectal Cancer Study Group.
Clinical Cancer Research.2008;14(6) March 15 1767 - 1774.
2008
Der Tod als Tabu, Wissensdefizit und Kostenfaktor - Der Umgang der Medizin mit der Transition von Leben und Tod.
Greil R.
in Ethik im Sog der Ökonomie
(Michael Fischer/Ingeborg Schrems) 2008, Seite 181 - 195
2008
Diagnostic Algorithms, Monitoring, Prognostication and Therapy in Chronic Myeloid Leukemia (CML) A Proposal of the Austrian CML Platform.
Valent P, Lion T, Wolf D, Sillaber C, Agis H, Petzer A, Lang A, Kalhs P, Geissler D, Greil R, Linkesch W, Burgstaller S, Thaler J, Gastl G.
Wiener Klinische Wochenschrift. 2008 Nov;120(21-22):697-709.
2008
Differential diagnostic challenge of chronic neutrophilic leukemia in a patient with prolonged leukocytosis.
Neureiter D, Kemmerling R, Ocker M, Seidlhofer C, Faber V, Stöcher M, Greil R, Dietze O.
Journal of Hematopathology. 2008 Jul;1(1):23-7. Epub 2008 Apr 19.
2008
Differential expression of GHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon.
Hohla F, Moder A, Mayrhauser U, Hauser-Kronberger C, Schally AV, Varga JL, Zarandi M, Buchholz S, Huber R, Aigner E, Ritter M, Datz C.
Int J Oncol. 2008 Jul;33(1):137-43.
2008
Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Heinrich E, Schally AV, Buchholz S, Rick FG, Halmos G, Mile M, Groot K, Hohla F, Zarandi M, Varga JL.
Prostate. 2008 Dec 1;68(16):1763-72.
2008
Erythropoietins in cancer patients: ESMO Recommendations for use.
Greil R, Thödtmann R, Roila F.
Ann Oncol. 2008 May;19 Suppl 2:ii113-5.
2008
ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO recommendations for the applications.
Greil R, Psenak O, Roila F.
Ann Oncol. 2008 May; 19Suppl 2:ii116-8.
2008
Expertenstatement Medikamentöse Therapie bei Magenkarzinom.
Wöll E, De Vries A, Eisterer, Greil R, Hejna M, Keil F, Stein H, Zacherl J.
Anticancer Research. 2008 Mar-Apr;28(2B):1213-9. Review.
2008
Feedback zu Fragen: Aktuelle Aspekte zum Mammakarzinom
Mlineritsch B
2008
Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.
Fischer H, Taylor N, Allerstorfer S, Grusch M, Sonvilla G, Holzmann K, Setinek U, Elbling L, Cantonati H, Grasl-Kraupp B, Gauglhofer C, Marian B, Micksche M, Berger W.
Molecular Cancer Therapeutics. 2008 Oct;7(10):3408-19.
2008
Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
Seitz S, Hohla F, Schally AV, Moder A, Engel JB, Horn F, Varga J, Zarandi M, Ortmann O, Köster F, Buchholz S.
Oncology Reports. 2008 Nov;20(5):1289-94.
2008
Is Chemoendocrine Treatment without Alternative? Editorial.
Greil R.
Breast Care. 2008, 3:231-235.
2008
MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, Eichenberger K, Greil R, Tinhofer I.
Journal of Clinical Oncology. 2008 May 10; 26(14):2252-7.
2008
Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer
Arkenau H-T, Graeven U, Stephan Kubicka, Axel Grothey, Christina Englisch-Fritz, Albrecht Kretzschmar, Greil R, Werner Freier, Thomas Seufferlein, Axel Hinke, Hans-Joachim Schmoll, Wolff Schmiegel, Rainer Porschen, on Behalf of the AIO Colorectal Study Group
Clinical Colorectal Cancer. January 2008, 60 - 64.
2008
Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.
von Moos R, Caspar CB, Thürlimann B, Angst R, Inauen R, Greil R, Bergstrom B, Schmieding K, Pecherstorfer M.
Annals of Oncology. 2008 Jul;19(7):1266-70. Epub 2008 Mar 11.
2008
SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a.
Seyfried I, Hofbauer S, Stoecher M, Greil R, Tinhofer I.
Blood. 2008 Sep 1;112(5):2168; author reply 2169. No abstract available.
2008
Tag der Darmgesundheit in Salzburg
Greil R
Magazin des Vereins für Darmkrebsinformation, Ausgabe 2/2008
2008
Tumour-immune cell interactions modulated by chemokines.
Jöhrer K, Pleyer L, Olivier A, Maizner E, Zelle-Rieser C, Greil R.
Expert Opinion on Biological Therapy. 2008 Mar;8(3):269-90. Review.
2008
Wert und Kosten von Leben und Tod in der Medizin.
Der Verteilungskampf in und um die Medizin und die ethischen Auswirkungen auf Individuum und Gesellschaft
Greil R.
In Weingartner P. (Editor) Rohstoff Mensch, das flüssige Gold der Zukunft? Ist Ethik privatisierbar?
(S.83 - 118) Frankfurt: Peter Lang
2008
2007
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group.
British Journal of Cancer. 2007 Oct 22;97(8):1021-7. Epub 2007 Sep 25.
2007
ASCO 2007 Neue Daten aus Chicago.
Greil R.
IATROS Haematologie und Onkologie. 03/2007 66-67
2007
Contribution of anti-cyclic citrullinated peptide antibody and rheumatoid factor to the diagnosis of arthropathy in haemochromatosis.
Aigner E, Schmid I, Osterreicher CH, Zwerina J, Schett G, Strasser M, Niksic F, Hohla F, Ramsauer T, Dorn U, Patsch W, Datz C.
Ann Rheum Dis. 2007 Sep;66(9):1249-51. Epub 2007 Apr 24.
2007
Dasatinib
Pleyer L, Greil R
Arzneimittelprofil Medizin Medien Austria, 11/2007 pp 1-16
2007
Entwicklungen und Perspektiven in der Behandlung der Lymphatischen Neoplasien.
Pleyer L, Desch P, Greil R.
in Lymphoproliferative Erkrankungen
R.Greil Uni-Med Science 2007, Seiten 139-155.
2007
Erklärung der Studienvorteile:
Schwedisch-österreichische Studie (SÖS) für PatientInnen mit Brusktrebs startet
Greil R
Krebs:hilfe 0672007
2007
Erythropoietins in cancer patients: ESMO recommendations for use.
Greil R, Thödtmann R, ESMO Guidelines Working Group.
Annals of Oncology. 2007 Apr; 18 Suppl 2:ii86-8.
2007
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).
Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R; Austrian Breast, Colorectal Cancer Study Group (ABCSG).
Breast Cancer Research and Treatment. 2008 Nov;112(1):203-13. Epub 2007 Dec 22
2007
Expertenempfehlung 2006 zur rationalen Zweitlinien-Therapie beim nicht-kleinzelligen Bronchuskarzinom [Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms].
Hilbe W, Aigner K, Dittrich C, Eckmayr J, Fiegl M, Flicker M, Forstner B, Greil R, Jamnig H, Krajnik G, Lang A, Mohn-Staudner A, Schinko H, Studnicka M, Pirker R, Ploner F, Rothmund J, Schiller L, Zabernigg A, Zöchbauer-Müller S.
Wiener Klinische Wochenschrift. 2007;119(7-8):259-66. Review. German. No abstract available.
2007
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group.
Journal of the National Cancer Institute. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11.
2007
Follikuläres Lymphom.
Egle A.
in Lymphoproliferative Erkrankungen
R.Greil Uni-Med Science, 2007, Seite 93 - 107
2007
Fulvestrant (Falsodex) in heavily pretreated postmenopausal patients with advanced breast cancer: Single centre clinical experience from the compassionate use programme.
Mlineritsch B, Psenak O, Mayer P, Moik M, Hauser-Kronberger C, Greil R.
Breast Cancer Research and Treatment. 2007 Nov;106(1):105-12. Epub 2007 Feb 13.
2007
Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt.
Hohla F, Schally AV, Kanashiro CA, Buchholz S, Baker B, Kannadka C, Moder A, Aigner E, Datz C, Halmos G.
Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18671-6. Epub 2007 Nov 14.
2007
Hematopoietic growth factors: ESMO Recommendations for the application.
Psenak O, Greil R.
Annals of Oncology. 18 (Supplement 2): ii89 - ii91, 2007.
2007
Herpesvirusinfektionen beim Tumorpatienten am Beispiel des Multiplen Myeloms
Pleyer L, Greil R
MMagazin Extra 1, 09/2007
2007
High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma.
Ressler S, Scheiden R, Dreier K, Laich A, Müller-Holzner E, Pircher H, Morandell D, Stein I, Viertler HP, Santer FR, Widschwendter A, Even J, Jansen-Dürr P, Capesius C, Zwerschke W.
Clin Cancer Res. 2007 Dec 1;13(23):7067-72.
2007
Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer?
Greil R, Stein HJ.
Lancet Oncology. 2007 Mar;8(3):189-90.
2007
Massive Bone Marrow Infiltration in Colon Carcinoma after Therapy with Activated Protein C.
Pleyer L, Went P, Russ G, Prinz E, Faber V, Röwert HJ, Karlbauer R, Greil R.
Wiener Klinische Wochenschrift. 2007;119(7-8):254-8.
2007
Mitochondrial phosphate-carrier deficiency: a novel disorder of oxidative phosphorylation.
Mayr JA, Merkel O, Kohlwein SD, Gebhardt BR, Böhles H, Fötschl U, Koch J, Jaksch M, Lochmüller H, Horvath R, Freisinger P, Sperl W.
American Journal of Human Genetics. 2007 Mar;80(3):478-84. Epub 2007 Jan 10.
2007
Morbus Hodgkin.
Greil R.
in Lymphoproliferative Erkrankungen
R.Greil Uni-Med Science, 2007, Seite 43,67
2007
Neue Antithrombotika - Heparine und Vitamin K - Antagonisten - geht eine Ära zu Ende ?
Rosenlechner S
Salzburger Arzt, 2007 März, Seite 37-43
2007
Neue Antithrombotika - Heparine und Vitamin K - Antagonisten - geht eine Ära zu Ende?
Rosenlechner S
Der Salzburger Arzt. 2007 März, 37-43.
2007
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch C, Rudas M, Greil R, Wenzel C, Singer CF, Haid A, Pöstlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel C, Jakesz R; ABCSG-14.
Journal of Clinical Oncology. 2007 May 20;25(15):2012-8.
2007
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ; AIO Colorectal Study Group.
Journal of Clinical Oncology. 2007 Sep 20;25(27):4217-23. Epub 2007 Jun 4.
2007
Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.
Buchholz S, Schally AV, Engel JB, Hohla F, Heinrich E, Koester F, Varga JL, Halmos G.
Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):1943-6. Epub 2007 Jan 29.
2007
Regulation of apoptosis.
Pleyer L, Tinhofer I, Greil R.
in ESMO Handbook of principles of translational Research
Hakan Mellstedt, Dirk Schrijvers, Dimitrios Bafaloukos, Richard Greil Informa healthcare 2007, Seite 67 - 69
2007
The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
Taucher S, Steger GG, Jakesz R, Tausch C, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M; Austrian Breast and Colorectal Cancer Study Group-07.
Breast Cancer Research and Treatment. 2008 Nov;112(2):309-16. Epub 2007 Dec 14.
2007
The Role of Imaging in Malignant Lymphoma: A critical View on PET Scanning in Current Clinical Practice
Namberger K, Greil R
Imaging Decisions, 4/2007 Seite 22 - 31
2007
The Role of Imaging in Malignant Lymphoma: A critical View on PET Scanning in Current Clinical Practice.
Namberger K, Greil R.
Imaging Decisions. 4/2007 22 - 31.
2007
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R; Austrian Breast and Colorectal Cancer Study Group.
Journal of Clinical Oncology. 2007 Mar 1;25(7):820-8. Epub 2006 Dec 11.
2007
2006
A role of TRAIL in killing osteoblasts by myeloma cells.
Tinhofer I, Biedermann R, Krismer M, Crazzolara R, Greil R.
FASEB Journal. 2006 Apr;20(6):759-61. Epub 2006 Jan 25.
2006
Adjuvanter Einsatz von Trastuzumab (Herceptina) in der klinischen Praxis außerhalb von klinischen Studien.
Greil R, H.J.Senn, Thörlimann B, Minckwitz G.v., Herrmann R, Jakesz R, Gnant M.
BREAST CARE, 2006; 1:96-101.
2006
Alemtuzumab (MabCampath) - Interview.
Greil R.
Krebs:Hilfe, 2006.
2006
Diagnose und Therapie der Plasmazelldyskrasien.
Greil R.
Der Salzburger Arzt. 20. Jg, Nr.4 April 2006: 23-29.
2006
Erlotinib beim nicht-kleinzelligen Lungenkrebs.
Greil R.
Ärztekrone. 27. Oktober 2006
2006
Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia.
Tinhofer I, Rubenzer G, Holler C, Hofstaetter E, Stoecher M, Egle A, Steurer M, Greil R.
Blood. 2006 Nov 1;108(9):2950-6. Epub 2006 Jul 6.
2006
Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: Case report and review of the literature.
Mian M, Rass C, Hutarew G, Kofler B, Fiegl M, Greil R.
Leukemia and Lymphoma. 2006 Aug;47(8):1683-5
2006
Gut begleitet.... Ist Sterben in Würde möglich? - Interview.
Greil R.
Salzburger Fenster. September 2006 SF 30/2006 Seite 9.
2006
IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses.
Falkensammer C, Jöhrer K, Gander H, Ramoner R, Putz T, Rahm A, Greil R, Bartsch G, Thurnher M.
Cancer Immunology Immunotherapy. 2006 Oct;55(10):1228-37. Epub 2006 Jan 28.
2006
Increased expression of extracellular proteins as a hallmark of human endothelial cell in vitro senescence.
Hampel B, Fortschegger K, Ressler S, Chang MW, Unterluggauer H, Breitwieser A, Sommergruber W, Fitzky B, Lepperdinger G, Jansen-Dürr P, Voglauer R, Grillari J.
Exp Gerontol. 2006 May;41(5):474-81. Epub 2006 Apr 19.
2006
Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study.
Marth C, Windbichler GH, Hausmaninger H, Petru E, Estermann K, Pelzer A, Mueller-Holzner E.
International Journal of Gynecological Cancer. 2006 Jul-Aug;16(4):1522-8.
2006
Klinische Praxis Aromataseinhibitoren: Upfront, Switch oder Extended?
Harbeck N, Jakesz R, Greil R, Jonat W, Maass N, Kaufmann M, Ortmann O, Possinger K, Steger G.
Breast Care. 2006: 1:37-43.
2006
Medikamentöse Palliativtherapie bei Tumorpatienten.
Hausmaninger H.
in Schmerzbehandlung in der Palliativmedizin, Springerverlag, 2006.
2006
Neueste Therapien und intensive Forschung im Kampf gegen Krebs.
Greil R.
Salzburger Fenster, September 2006 SF30/2006 Seite 15.
2006
Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome-dependent proteolysis.
Santer FR, Bacher N, Moser B, Morandell D, Ressler S, Firth SM, Spoden GA, Sergi C, Baxter RC, Jansen-Dürr P, Zwerschke W.
Cancer Res. 2006 Mar 15;66(6):3024-33.
2006
p16INK4A qualifies as a robust in vivo biomarker of cellular aging in human skin.
Ressler S, Bartkova J, Niederegger H, Bartek J, Scharffetter-Kochanek K, Jansen-Dürr P, Wlaschek M.
Aging Cell 2006 Oct; 5(5):379-389.
2006
Palliative therapy in glioblastoma multiforme: a multimodal concept.
Faber V, Thödtmann R, Marosi C.
Wiener Medizinische Wochenschrift. 2006 May;156(9-10):255-9. German.
2006
Purine antagonists for chronic lymphocytic leukaemia.
Steurer M, Pall G, Richard S, Schwarzer G, Bohlius J, Greil R, on behalf of the Cochrane Haematologic Malignancies Group
Cochrane Database of Systematic Reviews. 2006 Jul 19;3:CD004270.
2006
Schmerzdiagnostik bei Tumorpatienten.
Russ G.
in Schmerzbehandlung in der Palliativmedizin
Springerverlag 2006
2006
Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis.
Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R; Cochrane Haematologic Malignancies Group.
Cancer Treatment Reviews. 2006 Aug;32(5):377-89. Epub 2006 Jun 21. Review.
2006
Sorafenib (Bay 43-9006 (Sorafenib, Nexavar®), Pathopyhsiologie und klinische Anwendung für zielgerichtete Therapie)
Greil R.
Arzneimittelprofil, Dezember 2006, 3 - 15
2006
Sorafenib (Nexavar) - Ein großer Gewinn für die Onkologie - Interview.
Greil R.
krebs:hilfe, 6:2006
2006
Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.
Hohla F, Schally AV, Szepeshazi K, Varga JL, Buchholz S, Köster F, Heinrich E, Halmos G, Rick FG, Kannadka C, Datz C, Kanashiro CA.
Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14513-8. Epub 2006 Sep 18.
2006
Systemic application of granulocyte-colony stimulating factor and stem cell factor exacerbates excitotoxic brain injury in newborn mice.
Keller M, Simbruner G, Gorna A, Urbanek M, Tinhofer I, Griesmaier E, Sarkozy G, Schwendimann L, Gressens P.
Pediatric Research. 2006 Apr; 59 (4 Pt 1): 549-53.
2006
The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial.
Tinhofer I, Steurer M, Leitinger G, Rumpold H, Egle A, Erdel M, Greil R.
Haematologica-The Hematology Journal. 2006 Sep;91(9):1291-3.
2006
The still long and winding road to neoadjuvant systemic therapy (NST) as the standard of care and to the achievement of its prophecied goals in breast cancer - The con position.
Greil R.
Breast Care. 2006; 352-357. (Editorial)
2006
Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
Buchholz S, Keller G, Schally AV, Halmos G, Hohla F, Heinrich E, Koester F, Baker B, Engel JB.
Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10403-7. Epub 2006 Jun 26.
2006
Wie sterben wir? Wie schön ist der Tod? Wie teuer ist der Tod? - Die Palliativmedizin im Spannungsfeld der Ressouercenallokation
Greil R.
in Medizin- und Bioethik, Ethik transdisziplinär
Frankfurt a.M.: Peter Lang Europäischer Verlag der Wissenschaften 2006, Seite 351 - 370
2006
2005
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of chronic lymphocytic leukemia.
Hallek M, Stahel RA, Greil R.
Annals of Oncology. 2005 May;16(suppl_1):i50-i51. No abstract available
2005
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma.
Harrouseau JL, Greil R, Kloke O.
Annals of Oncology. 2005;16 Suppl 1:i45-7.
2005
1,10-Epoxyhypocretenolides from the Azorean Endemic Leontodon rigens (Asteraceae)
Zidorn C, Ellmerer EP, Konwalinka G, Ongania KH, Schwaha R, Greil R, Jöhrer K, Perry NB, Stuppner H
Letters in Organic Chemistry. Volume 2, Number 5, August 2005 , pp. 461-464(4).
2005
A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer.
Schippinger W, Jagoditsch M, Sorré C, Gnant M, Steger G, Hausmaninger H, Mlineritsch B, Schaberl-Moser R, Mischinger HJ, Hofbauer F, Holzberger P, Mittlböck M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group.
British Journal of Cancer. 2005 May 9;92(9):1655-62.
2005
Adjuvante und neoadjuvante Therapie des Pankreaskarzinoms.
Greil R.
Krebs:Hilfe, 1/05 S 34-36
2005
Chemotherapie im Alter.
Greil R, Faber V.
in Lebensqualität im Alter
Springer Verlag 2005
2005
Cilinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group.
Filipits M, Pohl G, Rudas M, Dietze O, Lax S, Grill R, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R.
Journal of Clinical Oncology. 2005 Feb 20;23(6): 1161-8.
2005
Continuous prednisolone versus conventional prednisolone with VMCP-Interferon-a2b as first-line chemotherapy in elderly patients with multiple myeloma.
Ludwig H, Spicka I, Klener P, Greil R, Adam Z, Gisslinger H, Tar-Kovacs G, Linkesch W, Maniatis A, Morant R, Schüller J, Niessner H, Preis P, Drach J, Schuster J.
British Journal of Haematology. 2005 Nov;131(3):329-37.
2005
Die (neo)adjuvante Therapie des Pankreascarcinoms.
Greil R.
Krebs :Hilfe 2/2005
2005
Diffuse large B cell lymphoma (DLBCL) as a second, non-clonal lymphoproliferative disease in a patient with IgM monoclonal gammopathy of undetermined significance (MGUS): case report and review of the literature.
Mian M, Tzankov A, Psenak O, Greil R, Fiegl M.
Leukemia & Lymphoma. 2006 May;47(5):940-3.
2005
ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients.
Fey MF, Greil R, Jost LM.
Annals of Oncology. 2005 May;16 Suppl 1:i48-i49
2005
ESMO recommendations for the application of hematopoietic growth factors.
Greil R, Jost LM.
Annals of Oncology. 2005;16 Suppl 1:i80-2.
2005
Expression of the high-risk human papillomaviruses type-18 and -45 E7 oncoproteins in cervical cancer biopsies.
Fiedler M, Ressler S, Campo-Fernández B, Laich A, Jansen L, Widschwendter A, Viertler H.P., Bacher N, Morandell D, Müller-Holzner E, Dürst M, Jansen-Dürr P, Zwerschke W.
J. Gen. Virol. 2005 Dec; 86(Pt 12):3235-3241.
2005
Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
Nachbaur D, Greinix HT, Koller E, Krieger O, Linkesch W, Kasparu H, Pober M, Hinterberger W, Hausmaninger H, Heistinger M, Ulsperger E, Karlhuber S, Schwinger W, Lindner B.
Annals of Hematology. 2005 Jul;84(7):462-73. Epub 2005 Feb 23.
2005
Long-term results of dose density therapy in patients with aggressive lymphoma.
Fridrik MA, Hausmaninger H, Linkesch W, Greil R, Krieger O, Baldinger C, Klocker J, Pont J, Oberaigner W.
Annals of Hematology. 2005 Apr;84(4):217-22. Epub 2004 Nov 6.
2005
PKC delta is involved in signal attenuation in CD3+ T cells.
Gruber T, Barsig J, Pfeifhofer C, Ghaffari-Tabrizi N, Tinhofer I, Leitges M, Baier G.
Immunology Letters. 2005 Jan 31;96(2): 291-3.
2005
Polyacetylenes from the Apiaceae Vegetables Carrot, Celery, Fennel, Parsley, and Parsnip and Their Cytotoxic Activities.
Zidorn C, Johrer K, Ganzera M, Schubert B, Sigmund EM, Mader J, Greil R, Ellmerer EP, Stuppner H.
Journal of Agricultural and Food Chemistry. 2005 Apr 6;53(7):2518-2523.
2005
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J; ABCSG and the GABG.
The Lancet. 2005 Aug 6-12;366(9484):455-62.
2005
Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, Hausmaninger H, Wischnewsky M, Possinger K.
Journal of Clinical Oncology. 2005 Jan 20;23(3):432-40.
2005
Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma.
Jöhrer K, Zelle-Rieser C, Perathoner A, Moser P, Hager M, Ramoner R, Gander H, Höltl L, Bartsch G, Greil R, Thurnher M.
Clinical Cancer Research. 2005 Apr 1;11(7):2459-65.
2005
2004
Biomarkers in non-small cell lung cancer prevention.
Hilbe W, Dirnhofer S, Greil R, Wöll E.
European Journal of Cancer Prevention. 2004 Oct;13(5):425-36.
2004
Das Prostatcarcinom des älteren Mannes aus der Sicht des internistischen Onkologen.
Greil R.
KREBSHILFE, geriatrische Onkologie, 2/04 26-28.
2004
Das Prostatcarcinom des älteren Mannes aus der Sicht des internistischen Onkologen.
Greil R.
ONKO-LOGISCH, 2004, in press = nicht p.r. Zeitschrift, KREBSHILFE 2/04, 26-28.
2004
Der Stellenwert der Hormontherapie in der Behandlung des Mammacarcinoms.
Greil R.
Der Salzburger Arzt, Seite 30-34, Juni 2004.
2004
Editorial zur adjuvanten und neoadjuvanten Therapie des NSCLC.
Greil R.
Iatros, Pulmonologie, 3, 3/2004.
2004
Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia.
Eisterer W, Bechter O, Söderberg O, Nilsson K, Terol M, Greil R, Thaler J, Herold M, Finke L, Günthert U, Montserrat E, Stauder R.
Leukemia Research. 2004 Oct;28(10):1043-51.
2004
Früherkennung von Tumorerkrankungen.
Greil R.
Ärztekrone. Sonderausgabe Juli 2004 (5/2004): 4-6.
2004
Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study.
Hausmaninger H, Morack G, Heinrich B, Wallwiener D, Höffken K, Buksmaui S, Krejcy K, Miller MA, Possinger K.
American Journal of Clinical Oncology-Cancer Clinical Trails. 2004 Aug;27(4):429-35.
2004
Is higher income and educational status associated with poorer outcome in patients with Hodgkin's disease?
Holzner B, Fischhofer M, Kemmler G, Kopp M, Sperner-Unterweger B, Krugmann, J, Dirnhofer S, Greil R.
European Journal of Haematology. 2004 Nov;73(5):318-24.
2004
Neoadjuvante und adjuvante Therapiekonzepte: Paradigmenwechsel beim Bronchuscarcinom?
Greil R.
IATROS Pulmonologie. 14-17, 3/2004.
2004
Normative data for functional assessment of cancer therapy--general scale and its use for the interpretation of quality of life scores in cancer survivors.
Holzner B, Kemmler G, Cella D, De Paoli C, Meraner V, Kopp M, Greil R, Fleischhacker WW, Sperner-Unterweger B.
Acta Oncologica. 2004;43(2):153-60.
2004
Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure.
Mlineritsch B, Mayer P, Rass C, Reiter E, Russ G, Vesenmayer G, Oberaigner W, Hausmaninger H.
Onkologie. 2004 Oct;27(5):441-6.
2004
Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer.
Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M, Jakesz R, Horvat R; Austrian Breast and Colorectal Cancer Study Group.
Annals of Surgery. 2004 Aug;240(2):306-12.
2004
Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr.
Holzner B, Kemmler G, Kopp M, Nguyen-Van-Tam D, Sperner-Unterweger B, Greil R.
European Journal of Haematology. 2004 Jun;72(6):381-9.
2004
Systemic Alambda amyloidosis associated with vascular fragility.
Laimer M, Kaindl K, Emberger M, Hawranek T, Lanschützer CM, Bauer JW, Linke RP, Mlineritsch B, Hintner H.
Journal der Deutschen Dermatologischen Gesellschaft. 2004 Nov;2(11):934-9. German.
2004
Tracing surfactant transformation from cellular release to insertion into an air-liquid interface.
Haller T, Dietl P, Stockner H, Frick M, Mair N, Tinhofer I, Ritsch A, Enhorning G, Putz G.
American Journal of Physiology-Lung Cellular and Molecular Physiology. 2004 May;286(5):L1009-15.Epub 2004 Jan 2.
2004
Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1.
Jöhrer K, Janke K, Krugmann J, Fiegl M, Greil R.
Clinical Cancer Research. 2004 Mar 15;10(6):1901-10.
2004
Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial.
Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R, Hermann R, Doelken G, Koch P, Oertel J, Roller S, Worst P, Bischof H, Glunz A, Greil R, von Kalle K, Schalk KP, Hasenclever D, Brosteanu O, Duehmke E, Georgii A, Engert A, Loeffler M, Diehl V, Mueller RP, Willich N, Fischer R, Hansmann ML, Stein H, Schober T, Koch B; German Hodgkin's Lymphoma Study Group.
Annals of Oncology. 2004 Feb;15(2):276-82.
2004
Unfavourable prognosis of patients with trisomy 18q21 detected by fluorescence in situ hybridisation in t(11;18) negative, surgically resected, gastrointestinal B cell lymphomas.
Krugmann J, Tzankov A, Dirnhofer S, Fend F, Greil R, Siebert R, Erdel M.
Journal of Clinical Pathology. 2004 Apr;57(4):360-364.
2004
2003
A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer.
Paridaens R, Van Aelst F, Georgoulias V, Samonnig H, Cocquyt V, Zielinski C, Hausmaninger H, Willemse P, Boudraa Y, Wildiers J, Ramazeilles C, Azli N.
Annals of Oncology. 2003 Mar;14(3):433-40.
2003
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
Kühr T, Burgstaller S, Apfelbeck U, Linkesch W, Seewann H, Fridrik M, Michlmayr G, Krieger O, Lutz D, Lin W, Pont J, Köck L, Abbrederis K, Baldinger C, Buder R, Geissler D, Hausmaninger H, Lang A, Zabernigg A, Duba C, Hilbe W, Eisterer W, Fiegl M, Greil R, Gastl G, Thaler J; Austrian CML Study Group.
Leukemia Research. 2003 May;27(5):405-11.
2003
Adulte Stammzellen - Eine Alternative?
Greil R.
in Science and Society, Vol. 1
Seismo Verlag, Zürich, pp.116
2003
Delayed addition of deoxycytidine protects normal CD34+ cells against cytotoxicity of gemcitabine without compromising its activity against human leukemic cells.
Tiefenthaler M, Hohla F, Strasser-Wozak E, Bacher N, Mühlmann O, Wein W, Konwalinka G.
Stem Cells. 2003;21(3):266-71.
2003
Diagnosis, Therapy and Prophylaxis of Fungal Diseases.
Ressler S, Würzner R.
Mycoses Vol. 46 (7)(2003): 245-286.
2003
Enhanced MTT-reducing activity under growth inhibition by resveratrol in CEM-C7H2 lymphocytic leukemia cells.
Bernhard D, Schwaiger W, Crazzolara R, Tinhofer I, Kofler R, Csordas A.
Cancer Letters. 2003 Jun 10;195(2):193-9.
2003
High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin.
Pohl G, Rudas M, Dietze O, Lax S, Markis E, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R, Filipits M.
Journal of Clinical Oncology. 2003 Oct 1;21(19):3594-600.
2003
Impact of pretreatment thrombocytosis on survival in primary breast cancer.
Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C, Galid A, Steger G, Jakesz R; Austrian Breast and Colorectal Cancer Study Group.
Thrombosis and Haemostasis. 2003 Jun;89(6):1098-106.
2003
In vitro studies on the immunosuppressive effect of 2',2'-difluorodeoxycytidine (dFdC) and its metabolite 2',2'-difluorodeoxyuridine (dFdU).
Tiefenthaler M, Hohla F, Irschick E, Strasser-Wozak E, Bacher N, Mühlmann O, Wein W, Konwalinka G.
Immunobiology. 2003;207(2):149-57.
2003
Longer failure-free survival interval of Epstein-Barr virus-associated classical Hodgkin's lymphoma: a single-institution study.
Krugmann J, Tzankov A, Gschwendtner A, Fischhofer M, Greil R, Fend F, Dirnhofer S.
Modern Pathology. 2003 Jun;16(6):566-73.
2003
Nosocomial enterobacter meningitis: risk factors, management, and treatment outcomes.
Parodi S, Lechner A, Osih R, Vespa P, Pegues D.
Clinical Infectious Diseases. 2003 Jul 15;37(2):159-66. Epub 2003 Jul 9.
2003
Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases.
Tzankov A, Krugmann J, Fend F, Fischhofer M, Greil R, Dirnhofer S.
Clinical Cancer Research. 2003 Apr;9(4):1381-6.
2003
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P, Gnant M, Haider K, Mlineritsch B, Tschurtschenthaler G, Steger G, Seifert M, Kubista E, Samonigg H; Austrian Breast And Colorectal Cancer Study Group.
Onkologie. 2003 Apr;26(2):115-9.
2003
Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, Tausch C, Fridrik M, Wette V, Steger G, Hausmaninger H.
Journal of Clinical Oncology. 2003 Mar 15;21(6):984-90.
2003
Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group.
Jakesz R, Samonigg H, Gnant M, Kubista E, Depisch D, Kolb R, Mlineritsch B, Mischinger HJ, Menzel RC, Steindorfer P, Kwasny W, Tausch C, Stierer M, Taucher S, Seifert M, Hausmaninger H; Austrian Breast & Colorectal Cancer Study Group.
Annals of Surgery. 2003 Apr;237(4):556-64.
2003
Stevens-Johnson syndrome associated with Malarone antimalarial prophylaxis.
Emberger M, Lechner AM, Zelger B.
Clinical Infectious Diseases. 2003 Jul 1;37(1):e5-7. Epub 2003 Jun 18.
2003
Tetrocarcin-A-induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2--independent pathway.
Anether G, Tinhofer I, Senfter M, Greil R.
Blood. 2003 Jun 1;101(11):4561-8. Epub 2003 Jan 30.
2003
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools.
Greil R, Anether G, Johrer K, Tinhofer I.
Journal of Leukocyte Biology. 2003 Sep;74(3):311-30. Review.
2003
Tuning the rheostat of the myelopoietic system via Fas and TRAIL.
Greil R, Anether G, Johrer K, Tinhofer I.
Critical Reviews in Immunology. 2003;23(4):301-22. Review.
2003
2002
Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer
Jakesz R, Hausmaninger H, Samonigg H
European Journal of Cancer 2002 Feb; 38 (3) : 327 - 32. Review
2002
Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia.
Anether G, Marschitz I, Tinhofer I, Greil R.
Blood, 2002 Jan 15;99(2):722-3.
2002
Overexpression of hypoxia-inducible factor lalpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.
Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G; Austrian Breast and Colorectal Cancer Study Group
Clinical Cancer Research 2002 Jun; 8 (6): 1831-7.
2002
Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5
Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Mlineritsch B, Steindorfer P, Kwasny Wir berichten über, Fridrik M, Steger G, Wette V, Samonigg H; Austrian Breast and Colorectal Cancer Study Group Trial 5
Journal of Clinical Oncology 2002 Dec 15;20 (24): 4621-7
2002
Stressful death of T-ALL tumor cells after treatment with the anti-tumor agent Tetrocarcin-A.
Tinhofer I, Anether G, Senfter M, Pfaller K, Bernhard D, Hara M, Greil R.
FASEB J. 2002 Aug;16(10):1295-7. Epub 2002 Jun 7.
2002
The impact of hemoglobin levesl on fatigue and quality of life in cancer patients.
Holzner B, Greil R, Kemmler G, Kopp M, Zeimet G, Raderer M, Hejna M, Zöchbauer S, Krajnik G, Huber H, Sperner-Unterweger B.
ANNALS OF ONCOLOGY,13,965-973, 2002
2002
Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoed tissue type with cladribine: a phase II study.
Jäger G, Neumeister P, Brezinschek R, Hinterleitner T, Fiebiger, Pnez M, Neumann HJ, Mlineritsch B, DeSantis M, Quehenberger F, Chott A, Beham-Schmid C, Höfler G, Linkesch W, Raderer M.
Journal of Clinical Oncology 2002 Sep 15;20 (18): 3872-7
2002
2001
Biclonal bacteremia due to Stenotrophomonas maltophilia in a cancer patient
Lechner A, Hindler JF, Nelson SF
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 2001 Sep;20(9):673-5
2001
Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C.
Hilbe W, Kühr T, Apfelbeck U, Fridrik M, Seewann H, Stöger M, Linkesch W, Pont J, Baldinger C, Hartner E, Bernhart M, Geissler D, Krieger O, Lang A, Lin W, Ludwig H, Duba C, Greil R, Gast G, Thaler J.
Leuk Lymphoma. 2001 Nov-Dec;42(6):1283-8.
2001
Evaluation of the United States Food and Drug Administration-approved scoring an test system of HER-2 protein expression in breast cancer.
Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group.
Clinical Cancer Research 2001 Jun; 7 (6): 1669-75.
2001
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.
Dühmke E, Franklin J, Pfreundschuh M, Sehlen S, Willich N, Rühl U, Müller RP, Lukas P, Atzinger A, Paulus U, Lathan B, Rüffer U, Sieber M, Wolf J, Engert A, Georgii A, Staar S, Herrmann R, Beykirch M, Kirchner H, Emminger A, Greil R, Fritsch E, Koch P, Drochtert A, Brosteanu O, Hasenclever D, Loeffler M, Diehl V.
J Clin Oncol. 2001 Jun 1;19(11):2905-14.
2001
Oligella ureolytica in blood culture: contaminant or infection?
Lechner A, Bruckner DA
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2001 Feb;20(2):142-3
2001
Prognostic relevance of thre histological grading methods in breast cancer
Latinovic L, Heinze G, Birner P, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Gnant M, Jakesz R, Oberhuber G; Austrian Breast and Colorectal Cancer Study Group
International Journal of Oncology 2001 Dec; 19 (6) : 1271-7
2001
Quality of life measurement in oncology--a matter of the assessment instrument?
Holzner B, Kemmler G, Sperner-Unterweger B, Kopp M, Dünser M, Margreiter R, Marschitz I, Nachbaur D, Fleischhacker WW, Greil R.
Eur J Cancer. 2001 Dec;37(18):2349-56.
2001
2000
Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia: a comparison of three semiquantitation techniques
Marschitz I, Tinhofer I, Hittmair A, Egle A, Kos M, Greil R
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 113,219-229, 2000
2000
Expression of functional Interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.
Tinhofer I, Marschitz I, Henn T, Egle A, Greil R
Blood, 2000 Jan 15;95(2):610-618.
2000
Gastric cancer cell lines lack Fas Ligand (FasL) expression but kill T cells via a FasL-independent pathway.
Tinhofer I, Wykypiel H, Marschitz I, Henn T, Greil R.
GUT, 2000 May;46(5):738-740.
2000
Interferon-gamma in the first-line therapy of ovarian Cancer: a randomized phase III trial.
Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Müller-Holzner E, Marth C
British Journal of Cancer 2000 Mar; 82 (6): 1138-44
2000
1999
Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Kemmler G, Holzner B, Kopp M, Dünser M, Margreiter R, Greil R, Sperner-Unterweger B.
J Clin Oncol. 1999 Sep;17(9):2932-40.
1999
1998
Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia.
Hilbe W, Apfelbeck U, Fridrik M, Bernhart M, Niessner H, Abbrederis K, Michlmayr G, Pont J, Linkesch W, Hausmaninger H, Arneitz K, Baldinger C, Duba C, Eisterer W, Greil R, Konwalinka G, Niederwieser D, Gastl G, Thaler J.
Leuk Res. 1998 Oct;22(10):881-6.
1998
1997
Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.
Egle A, Villunger A, Marschitz I, Kos M, Hittmair A, Lukas P, Grünewald K, Greil R.
Br J Haematol. 1997 May;97(2):418-28.
1997
1995
Gastric malt lymphoma with crystalline immunoglobulin inclusions and secondary immunoblastic lymphoma in a cervical lymph node.
Fend F, Gabl C, Hittmair A, Greil R, Feichtinger H.
Pathol Res Pract. 1995 Oct;191(10):1053-8.
1995